CanceRx 2013

A conference of the MIT Laboratory for Financial Engineering

In collaboration with the National Cancer Institute
and with the participation of the American Cancer Society

Support from the Alfred P. Sloan Foundation is gratefully acknowledged

June 16-18, 2013
Cambridge, MA

CanceRx was an invitation-only conference that focused exclusively on new approaches to commercializing biomedical research in oncology through financial engineering. Bringing together representatives from key stakeholder communities—including academia and medical research centers, community hospitals, the biopharma industry, health plans, government agencies, patient advocacy groups, investment banks, hedge funds, credit rating agencies, biotech venture capitalists, and institutional and retail investors—the conference was organized into six sessions, each focusing on a specific aspect of the conference theme:

• Scientific and Engineering Challenges
• New Business Models
• Financing Structure, Marketing, and Investor Concerns
• Government, Healthcare Reform, and Non-Profits
• Technology Licensing and Intellectual Property Issues
• Credit Models and Debt Rating

To make the conference as productive as possible, we created working groups, comprised of individuals with domain-specific expertise, for each of the sessions. These groups convened prior to the conference and were tasked with the goal of identifying the most significant challenges within their session topic and providing potential solutions to be presented at the conference and vetted by the broader set of conference participants.

Conference Steering Committee: David B. Agus, University of Southern California; Edward Benz, Dana-Farber Cancer Institute; Douglas A. Dachille, First Principles Capital Management; Joseph Dear, CalPERS; Jacob Goldfield, private investor; H. Robert Horvitz, MIT; Robert Langer, MIT; Pablo Legorreta, Royalty Pharma; Frank McCormick, University of California, San Francisco; Robert C. Merton, MIT Sloan School of Management; Lita Nelsen, MIT Technology Licensing Office; Larry Norton, Memorial Sloan-Kettering Cancer Center; John Seffrin, American Cancer Society; Bruce Stillman, Cold Spring Harbor Laboratory; Marty Tenenbaum, Cancer Commons; Thomas Tombrello, Caltech.

David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and heads U.S.C.’s Westside Cancer Center and the Center for Applied Molecular Medicine. He is one of the world’s leading cancer doctors, and the co-founder of two pioneering personalized medicine companies, Navigenics and Applied Proteomics. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare and chairs the Global Agenda Council on Genetics for the World Economic Forum. He has received numerous awards, including the 2009 Geoffrey Beene Foundation’s Rockstar of Science Award. Dr. Agus’ first book, The End of Illness, was published in January 2012 by the Free Press Division of Simon & Schuster and is a New York Times #1 best seller. A PBS documentary called “The End of Illness with David Agus” aired nationwide in the fall of 2012.

Edward Benz graduated from Harvard Medical School in 1973 and received his training at Brigham and Women’s Hospital and the National Institutes of Health. He is president of Dana-Farber Cancer Institute, CEO of Dana-Farber/Partners CancerCare, director and principal investigator of Dana-Farber/Harvard Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Cancer Center. He is also a clinical hematologist and an active NIH-funded investigator. In addition, he is the Richard and Susan Smith Professor of Medicine, Professor of Pediatrics, and Professor of Pathology at Harvard Medical School. Dr. Benz’s research focuses on the molecular pathology of hemolytic anemias.

Douglas A. Dachille is one of the founders of First Principles Capital Management, LLC (FPCM) and currently serves as Chief Executive Officer and Chief Investment Officer. His background and knowledge encompass all aspects of asset management, structured finance, and risk management. Immediately prior to co-founding FPCM, Mr. Dachille was President and Chief Operating Officer of Zurich Capital Markets Inc. (“ZCM”), an integrated alternative investment asset management and structured product subsidiary of Zurich Financial Services.

Preceding his tenure at ZCM, Mr. Dachille was a Managing Director for J.P. Morgan where he was the Global Head of Proprietary Trading and a member of the Management Committee of the Investment Bank. He was responsible for building the Global Relative Value Proprietary Trading business, and in fiscal year 2000 this business was one of the most important contributors to both the pre-tax net income and economic value for J. P. Morgan. In addition, Mr. Dachille was responsible for managing the bank’s investment portfolios, for developing and executing economic and regulatory capital management strategies, and for designing and managing non-qualified employee deferred compensation plans. Mr. Dachille was Chairman of the firm’s Capital Committee and served as a trustee of the J. P. Morgan qualified benefit plans. Prior to his role in the Proprietary Positioning business, Mr. Dachille was responsible for building the Hybrid Derivatives business for J. P. Morgan beginning in 1991. The Hybrid Derivatives business was developed to provide clients with customized derivatives solutions to complex problems and continues to be a significant revenue contributor for J. P. Morgan.

Mr. Dachille earned his Bachelor of Science in a special joint program through Union University and Albany Medical College, and later was a Pew Scholar in Medicine, Arts and Social Sciences at the University of Chicago.

Joseph A. Dear is the Chief Investment Officer of the California Public Employees’ Retirement System (CalPERS). Mr. Dear oversees all asset classes in which CalPERS invests, including domestic and international equity, Treasury and agency debt, high‐yield bonds, mortgage backed securities, real estate, corporate governance, currency overlay, securities lending, venture capital, leveraged buyouts, commodities, infrastructure and hedge funds.

Mr. Dear is responsible for the strategic plan for the CalPERS Investment Office, including tactical asset allocation, risk management, business development, budget authority, new investment programs, trading technology, staffing, and back office operations.

Mr. Dear joined CalPERS in March 2009 after previously serving as the Executive Director for the Washington State Investment Board. He previously served as Chief of Staff for Washington State Governor Gary Locke. Mr. Dear also served in the Clinton Administration as Assistant Secretary of Labor at the Occupational Safety and Health Administration. Prior to his federal service, Mr. Dear was Director of the Washington State Department of Labor and Industries where he managed the state’s workers’ compensation insurance fund and served as an ex‐officio member of the Washington State Investment Board including two terms as Chair. Earlier, he was Research Director for the Washington State Labor Council (AFL‐CIO).

Two of the programs he managed at OSHA and the Department of Labor and Industries received Innovations in Government Awards from the Ford Foundation and the Kennedy School of Government at Harvard University.

Currently Mr. Dear also serves as Chair of the U.S. Security and Exchange Commission (SEC) Investor Advisory Committee, and is a board member of the Pacific Pension Institute. He also served four terms as Chair of the Council of Institutional Investors. Mr. Dear received a Bachelor of Arts degree in Political Economy from The Evergreen State College in Olympia, Washington.

Jacob Goldfield is a successful option trader who retired as a senior partner of Goldman Sachs. He was later the Chief Investment Officer of Soros Fund Management and Quantum. He has invested and served as a board member for several private biotech companies in the past including serving as Chairman of the Board of CombinatorX Inc. Mr. Goldfield holds an A.B. in physics from Harvard College.

H. Robert Horvitz received the Nobel Prize in Physiology or Medicine in 2002. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT); an Investigator of the Howard Hughes Medical Institute; Neurobiologist (Neurology) at the Massachusetts General Hospital; and a Member of the MIT McGovern Institute for Brain Research; and a Member of the MIT Koch Institute for Integrative Cancer Research.

Dr. Horvitz received S.B. degrees in Mathematics and in Economics from MIT in 1968. He performed his graduate studies at Harvard University in the laboratories of Drs. James Watson and Walter Gilbert and received his Ph.D. in Biology in 1974. Dr. Horvitz then joined Dr. Sydney Brenner as a postdoctoral fellow at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England. Since 1978, Dr. Horvitz has been an Assistant, Associate and Full Professor in the Department of Biology at the Massachusetts Institute of Technology. His research involving C. elegans has helped define evolutionarily conserved molecular genetic pathways important in human biology and human disease, including the pathway responsible for programmed cell death, or apoptosis.

Dr. Horvitz is a member of the Board of Trustees of the Massachusetts General Hospital and is Chairman of the Board of Trustees of the Society for Science and the Public. He was President of the Genetics Society of America. He has served on many editorial boards, visiting committees and advisory committees. He was co-chair of the National Cancer Institute Working Group on Preclinical Models for Cancer and a member of the National Human Genome Research Institute Advisory Council, of the U.S. National Academies of Science and Institute of Medicine Committee on Guidelines for Human Embryonic Stem Cell Research and of the American Academy of Arts and Sciences Committee on Advancing Research in Science and Engineering. He is a member of the Advisory Committee to the Director of the National Institutes of Health and of the Council of the U.S. Institute of Medicine.

Dr. Horvitz received the U.S. National Academies of Science Award in Molecular Biology; the Charles A. Dana Award for Pioneering Achievements in Health; the Ciba-Drew Award for Biomedical Science; the General Motors Cancer Research Foundation Alfred P. Sloan, Jr. Prize; the Gairdner Foundation International Award; the March of Dimes Prize in Developmental Biology; the Genetics Society of America Medal; the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience; the Wiley Prize in the Biomedical Sciences; the Peter Gruber Foundation Foundation Genetics Prize; the American Cancer Society Medal of Honor; the Alfred G. Knudson Award of the National Cancer Institute; and the U.K. Genetics Society Mendel Medal.

Dr. Horvitz is a member of the U.S. National Academy of Sciences, the U.S. Institute of Medicine and the American Philosophical Society and is a Foreign Member of the Royal Society of London. He is a Fellow of the American Academy of Arts and Sciences and of the American Academy of Microbiology. Dr. Horvitz received an Honorary M.D. from the University of Rome and Honorary D.Sc. degrees from Cambridge University and Pennsylvania State University.

Dr. Horvitz has been a consultant to the Novartis Institutes for Biomedical Research and the venture capital company MPM Capital as well as to a number of biotechnology companies, and he cofounded the biotechnology companies NemaPharm, Inc., Idun Pharmaceuticals, Enlight BioSciences and Epizyme, Inc.

Robert Langer is an Institute Professor at MIT (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). He has written approximately 1,200 articles. These articles have been cited over 80,000 times; his h-index of 139 is the highest of any engineer in history. He has 815 issued and pending patents worldwide. His patents have licensed or sublicensed to over 250 companies. He served as Chairman of the FDA’s SCIENCE BOARD (it’s highest advisory board) from 1999-2002. His over 200 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation, the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize (largest US medical prize), the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 20 honorary doctorates including honorary degrees from Harvard and Yale. Langer is one of the very few individuals ever elected to the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences. Photo Credit: Stu Rosner.

Pablo Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products, and currently serves as Chief Executive Officer. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations. Mr. Legorreta joined Lazard Frères et Cie in Paris in 1988, then moved to Lazard Frères & Co in New York in 1990. Mr. Legorreta currently serves as a Director of Giuliani SpA and is a founding member of Boston Children’s Hospital Medical Research Council, as well as a member of the Board of Trustees of The Allen-Stevenson School, the Park Avenue Armory and of the American-Austrian Foundation/Open Medical Institute. He received a degree in industrial engineering from Universidad Iberoamericana.

Frank McCormick is director of the University of California San Francisco (UCSF) Comprehensive Cancer Center and Cancer Research Institute, a multidisciplinary research and clinical care organization that is one of the largest matrix cancer centers in the Western United States. A native of Cambridge, England, he received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. He has been a Fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92. In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. McCormick’s current research interests center on the fundamental differences between normal and cancer cells that can allow the use of naturally occurring and engineered viruses as novel therapeutic strategies. Most recently, his work has focused on the adenovirus d11520, which lacks the gene E1b, an inhibitor of p53, and can therefore be exploited to selectively target cancer cells lacking p53. In addition to his position as director of the UCSF Cancer Center, Frank McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research in UCSF’s Department of Microbiology and Immunology. Dr. McCormick is the author of more than 200 scientific publications.

Robert C. Merton is the School of Management Distinguished Professor of Finance at the MIT Sloan School of Management. He is the University Professor Emeritus at Harvard University, and was the George Fisher Baker Professor of Business Administration (1988–98) and the John and Natty McArthur University Professor (1998–2010) at Harvard Business School. He previously served on the finance faculty of MIT Sloan from 1970 to 1988. Dr. Merton co-founded Long-Term Capital Management. He is currently resident scientist at Dimensional Fund Advisors, where he is developing a next-generation, integrated pension-management solution system that addresses the deficiencies associated with traditional defined-benefit and defined-contribution plans.

Dr. Merton received the Alfred Nobel Memorial Prize in Economic Sciences in 1997 for a new method to determine the value of derivatives. He is past president of the American Finance Association, a member of the National Academy of Sciences, and a Fellow of the American Academy of Arts and Sciences.

He is the author of Continuous-Time Finance and a co-author of Cases in Financial Engineering: Applied Studies of Financial Innovation; The Global Financial System: A Functional Perspective; Finance; and Financial Economics. Dr. Merton also has been recognized for translating finance science into practice. He received the inaugural Financial Engineer of the Year Award from the International Association of Financial Engineers in 1993, which also elected him a Senior Fellow. Derivatives Strategy magazine named him to its Derivatives Hall of Fame as did Risk magazine to its Risk Hall of Fame. He also received Risk’s Lifetime Achievement Award for contributions to the field of risk management. A Distinguished Fellow of the Institute for Quantitative Research in Finance and a Fellow of the Financial Management Association, Dr. Merton received the Nicholas Molodovsky Award from the CFA Institute.

Dr. Merton holds a BS in engineering mathematics from Columbia University, an MS in applied mathematics from the California Institute of Technology, and a PhD in economics from MIT.

Lita Nelsen is the Director of the Technology Licensing Office at MIT, where she has been since 1986. This office manages over 600 new inventions per year, negotiating over 100 licenses per year, and helping to start 25 new startups.

Ms. Nelsen earned B.S. and M.S. degrees in Chemical Engineering from MIT and an M.S. in Management from MIT as a Sloan Fellow. Prior to joining the MIT TLO she spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology.

Ms. Nelsen was the 1992 President of the Association of University Technology and was a founding board member of MIHR, an organization concerned with the use of IP in medical research for developing country diseases.

Ms. Nelsen is widely published in the field of technology transfer and university/industry collaborations. She is a co-founder of Praxis, the UK University Technology Transfer Training Programme for which she was made a Member of the British Empire.

Larry Norton is Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan-Kettering and Medical Director of the Evelyn H. Lauder Breast Center.

His research concerns the basic biology of cancer; the mathematics of tumor causation and growth; and the development of approaches to better diagnosis, prevention, and drug treatment of the disease. He is involved in many areas of research including identifying the genes that predispose people to cancer or that cause cancer, developing new drugs, monoclonal antibodies that target growth factor receptors, and vaccines. A major milestone in his research career was the development of an approach to therapy called “dose density,” or “sequential dose density.” This is a new and more effective way of using anticancer drugs, based on a mathematical model he developed with his colleagues, which maximizes the killing of cancer cells while minimizing toxicity.

He is currently the principal investigator of a program project grant from the National Cancer Institute (NCI) that is aimed at better understanding breast cancer in the laboratory and in bringing these advances into clinical practice.

On a national level, Dr. Norton was formerly the Chair of the Breast Committee of the NCI’s Cancer and Leukemia Group B. He was also President of the American Society of Clinical Oncology (ASCO) from 2001 to 2002, and was appointed by President Clinton to serve on the National Cancer Advisory Board (the board of directors of the NCI).

Among many awards over the course of his career, he received ASCO’s highest honor, the David A. Karnofsky Award, and was McGuire Lecturer at the San Antonio Breast Cancer Symposium. He is an author of more than 350 articles and many book chapters, have served as a visiting professor throughout the United States, Canada, South America, Europe, Israel, and Asia, and also have trained many cancer doctors and researchers.

After receiving his M.D. from the College of Physicians and Surgeons, Columbia University, Dr. Norton trained in Internal Medicine at the Albert Einstein College of Medicine.

John Seffrin has served as chief executive officer of the American Cancer Society Cancer Action Network (ACS CAN) since its inception in 2001. He also serves as CEO of the American Cancer Society, the world’s largest voluntary health organization and the parent organization of ACS CAN. Prior to coming to the American Cancer Society, Dr. Seffrin was professor of health education and chairman of the Department of Applied Health Science at Indiana University.

He served as president of the International Union Against Cancer (UICC) from 2002 to 2006, during which time he worked to revive UICC’s historic role as a global leader in tobacco control advocacy and served as its international spokesperson. Dr. Seffrin also served as chairman of the Board of Independent Sector (the largest US membership organization representing nonprofit organizations) from 2002 to 2005.

In 1999, Dr. Seffrin was selected to be a charter member of C-Change (formerly known as the National Dialogue on Cancer) Steering Committee, which is co-chaired by former President George H.W. Bush and former First Lady Barbara Bush. In 1997, Dr. Seffrin was appointed to the National Cancer Policy Board, and in 1999, he was appointed by Senator Dianne Feinstein to co-chair the National Cancer Legislation Advisory Board. He also served a four-year term on the Advisory Committee to the Director of the US Centers for Disease Control and Prevention.

Dr. Seffrin is a preeminent leader of the international tobacco control movement. He led the creation of the National Center for Tobacco-Free Kids (now the Campaign for Tobacco-Free Kids), serving as its initial board chair. He served on the Advisory Committee to Congress on Tobacco Policy and Public Health, co-chaired by Dr. C. Everett Koop and Dr. David Kessler; the US Surgeon General’s Advisory Committee on Smoking and Health; the President’s Commission on Improving Economic Opportunities in Communities Dependent on Tobacco Production While Protecting Public Health; and the Department of Health and Human Services Interagency Committee on Smoking and Health.

Ball State University, Purdue University, Thomas Jefferson University and Indiana University have bestowed honorary doctorates upon him in recognition of his more than three decades of esteemed leadership in the worldwide fight against cancer.

Bruce Stillman is President of Cold Spring Harbor Laboratory. A native of Australia, he graduated with a Bachelor of Science degree with first class honors at The University of Sydney and a Ph.D. at the John Curtin School of Medical Research at the Australian National University. He then moved to Cold Spring Harbor Laboratory as a Postdoctoral Fellow in 1979 and has been at the Laboratory ever since, being promoted to the scientific staff in 1981. Dr. Stillman has been Director of the Cancer Center at Cold Spring Harbor Laboratory since 1992, a position he still holds. In 1994, he succeeded Nobel Laureate James D. Watson as Director of Cold Spring Harbor Laboratory and was appointed President in 2003. Dr. Stillman’s research focuses on the mechanism and regulation of duplication of DNA and chromatin in cells, a process that ensures accurate inheritance of genetic information from one cell generation to the next. He was awarded the Order of Australian (AO) in 1999 for his medical research. He was elected to The Royal Society (UK), the National Academy of Sciences, the Australian Academy of Sciences and the American Academy of Arts and Sciences. Dr. Stillman was awarded the 2004 Alfred P. Sloan Prize from the General Motors Cancer Research Foundation and the 2010 Louisa Gross Horwitz Prize form Columbia University, both with Dr. Thomas Kelly of Memorial Sloan Kettering Cancer Center. He is a recipient of the American Cancer Society Basic Science Award from the Society of Surgical Oncology and the Curtin Medal from the Australian National University. He is the past co-chair of the Board of Scientific Counselors of the National Cancer Institute and was vice-chair of the National Cancer Policy Board. Currently, Dr. Stillman is a member of the Medical Advisory Board of the Howard Hughes Medical Institute, the Board of Life Sciences of the National Research Council, the advisory boards for Koch Institute for Integrative Cancer Research at MIT and the Lewis Sigler Institute at Princeton University and the Board of Scientific Advisors of the National Cancer Institute. He also consults for a number of corporations and foundations.

J. Marty Tenenbaum is the Founder and Chairman of Cancer Commons, a non-profit, open science community that compiles and continually refines information about cancer subtypes and treatments, based on the literature and actual patient outcomes.

Dr. Tenenbaum’s background brings a unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company’s business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Dr. Tenenbaum was also the Founder and Chairman of CollabRx, a provider of Web-Based applications and services that help cancer patients and their physicians select optimal treatments and trials, which was acquired by Tegal in 2012.

Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon’s new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

Thomas A. Tombrello is a native of Texas, who earned his BA, MA and PhD degrees at Rice University in Houston. He came to Caltech in 1961, and except for a brief stint on the Yale faculty, has been here since then. A full professor of physics since 1971, Dr. Tombrello also served as Vice President and Director of Research at Schlumberger-Doll Research from 1987 to 1989. He was William R. Kenan, Jr. Professor at Caltech in 1997 – 2011, and was chair of the Division of Physics, Mathematics and Astronomy in August 1998 – 2008. He was also the Institute’s Technology Assessment Officer 1996-2010. In 2012 he was named the Robert H. Goddard Professor of Physics.

Dr. Tombrello and his research group are primarily involved in applying the techniques of theoretical and experimental physics to problems in materials science, surface physics, and planetary science. His ongoing research includes understanding the damage processes caused by megavolt ions in solids, microfluidic circuit elements, and non-linear financial phenomena.

He is a consultant for Schlumberger Ltd., Applied Minds Inc., FormFactor Inc., Lawrence Livermore National Laboratory, and University of Southern California. He is on the Board of Directors of the American Friends of Uppsala University and a Trustee of the London Institute for Mathematical Sciences – both non-profits.

June 16 – 18, 2013

Downloadable Agenda

*Moderator and Session Chair

Rob Armstrong is an entrepreneur and advisor and consultant to biotech and pharmaceutical companies on scientific, strategic, and transaction projects. Rob was previously at Lilly from 1999-2011 in multiple senior executive roles including global Vice President of Medicinal Chemistry, Vice President of Global External R&D and Chorus, and the investment and scientific committees of Lilly BioVentures. In these capacities, Rob participated in discovery and development of drug candidates across all therapeutic areas in the Lilly portfolio. He also drove innovative new strategies for improved biopharmaceutical R&D including alternative development and funding approaches. Rob also led the corporate scientific diligence for all M&A, licensing, and partnering transactions. From 1996-1999 Rob was Director of small molecule R&D at Amgen where he helped start Amgen’s entry into small molecule therapeutics. Rob was an Associate Professor of Chemistry and Biochemistry at UCLA from 1986-1996 and focused his research on the elucidation of mechanism of action of bioactive natural products in multiple therapeutic areas. Rob received his B.S. from UCSD and his Ph. D. from CSU.

Michael J. Baek is the Managing Director of Structured Finance at First Principles Capital Management, LLC (FPCM). Mr. Baek has more than 22 years of structured finance & capital markets experience, and a strong background in related accounting, regulatory and tax matters. Prior to joining FPCM, he was a Managing Director at Zurich Capital Markets. While there, Mr. Baek was responsible for new product development and securitization activities. Prior to joining ZCM, Mr. Baek was a Senior Vice President at Lehman Brothers Inc. where he was responsible for principal finance activities covering financial institutions. In addition, Mr. Baek was responsible for advising financial institutions on various fixed income and capital markets strategies including structured finance & securitization, balance sheet and capital management, derivatives strategies, and accounting / regulatory developments. Prior to joining Lehman, Mr. Baek worked at TMG Financial Products where he was responsible for structured product marketing. Prior to TMG, Mr. Baek worked at Goldman Sachs & Co where he was responsible for advising financial institutions on balance sheet restructuring and asset/liability management. Mr. Baek earned a Bachelor of Science in Aerospace Engineering from The State University of New York at Buffalo, and Master of Science in Operations Research from Stanford University.

Edward Benz, Dana-Farber Cancer Institute. Please see steering committee members tab.

Jim Broderick, M.D., is a Partner on the Morgenthaler Life Sciences Team and invests in companies developing innovative therapeutic products in the biotech and medical device industries.

Dr. Broderick is a co-founder and Chairman at Promedior Pharmaceuticals, a company developing drugs to treat fibrotic diseases such as Idiopathic Pulmonary Fibrosis and Myelofibrosis. Dr. Broderick is a co-founder and Chairman at Ra Pharmaceuticals, a biotech company developing orally available and cell permeable peptide drugs. Jim was the founding CEO and currently serves as a Board member at SetPoint Medical, a company developing implantable neurostimulation devices to treat inflammatory diseases such as Crohn’s Disease and Rheumatoid Arthritis as an alternative to drug therapy. He is an investor and board member of several other novel biotech and medical device companies, including OncoMed Pharmaceuticals, the leader in the field of drugs targeting cancer cell pathways, and Spine Wave, a commercial stage company selling multiple innovative devices for minimally invasive spinal surgery.

Dr. Broderick opened Morgenthaler’s Boston Office in 2005 after spending several years in Silicon Valley. Jim is a graduate of MIT (Bachelors in Mechanical Engineering) and University of Massachusetts (Doctor of Medicine). He was a member of the Kauffman Fellows Program, a two-year educational fellowship sponsored by the Kauffman Center for Entrepreneurial Leadership designed to train future venture capitalists and leaders of high growth companies.

Britt Canady is a Managing Director and the Group Head in Leveraged Finance with Bank of America Merrill Lynch. Britt graduated the University of North Carolina with a BA and Honors in Religious Studies, and a minor in business, in 1992; and graduated UNC law school with JD honors and UNC-Kenan Flagler with a MBA in 1996. Upon completing graduate school, Britt practiced finance law with the firm Womble Carlyle Sandridge and Rice until 2000. Britt joined the debt capital markets team of Banc of America Securities, now Merrill Lynch, in 2000, and has been with the leveraged finance group since then. He became a group head in 2007.

Lewis C. Cantley recently became the director of the newly established Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital. Dr. Cantley is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences USA. He is one of the world’s most pre-eminent scientists in both basic and clinical research and a Cornell University alumnus. Dr. Cantley has made significant advances in cancer research stemming from his discovery of the signaling pathway phosphoinositide 3-kinase (PI3K) in the mid-’80s, which explains the growth of a cell and has major implications in cancer. His pioneering research discovered that human cancers frequently have mutations in PI3K and, for the past three decades, has worked to identify new treatments for cancers that result from defects in the pathway. This discovery, which has led to one of the most promising avenues for the development of personalized cancer therapies, has since resulted in revolutionary treatments for cancer, diabetes and autoimmune diseases.

Most recently, Dr. Cantley’s research has focused on characterizing the mechanism by which PI3K is activated by growth factors and cancer-causing oncogenes, and elucidating PI3K’s pathways, including Akt/PKB — critical proteins that regulate cell survival and proliferation in normal and cancer cells. In the course of his work, Dr. Cantley’s laboratory has revealed the structural basis for regulated interaction of these signaling proteins, and this technique has led to a bioinformatics approach for predicting signaling pathways on the basis of gene sequences.

Dr. Cantley is currently exploring the role of the PI3K pathway in cancer and diabetes by developing mouse models in which genes for enzymes in this pathway are altered. Last year, he was awarded a $15 million grant from Stand Up 2 Cancer to lead a team of researchers to bring new cancer treatments to patients faster by investigating the role of PI3K in the development of breast, ovarian and endometrial cancers.

Dr. Cantley graduated summa cum laude in 1971 with a Bachelor of Science degree in chemistry from West Virginia Wesleyan College and obtained a Ph.D. in biophysical chemistry from Cornell University in 1975. He conducted postdoctoral research at Harvard University from 1975 until 1978, when he was appointed assistant professor of biochemistry and molecular biology at Harvard University’s Faculty of Arts and Sciences. Dr. Cantley was appointed as professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992, a position he held until 2003.

Eric L. Chen is Senior Manager of Corporate Development & Strategy at Onyx Pharmaceuticals where he helps lead the company’s strategy and innovation efforts. Prior to Onyx, he held various marketing and new product planning roles at Biogen Idec and Halozyme Therapeutics. Earlier in his career, he worked at the Cap Gemini Ernst & Young Center for Business Innovation. Eric also researches and writes about organizational strategy and innovation. His work has been published in leading academic journals, including Administrative Science Quarterly, California Management Review, Strategic Entrepreneurship Journal, and Strategic Management Journal. His latest research, in collaboration with Henry Chesbrough at UC Berkeley, focuses on open innovation in the pharmaceutical industry. Eric received his BS in economics from MIT and PhD in management science & engineering from Stanford University.

Doug Cole joined Flagship Ventures in 2001 where he focuses on Life Science investments. He wentto Flagship with significant industry experience and a strong academic background. Doug holds an AB magna cum laude with High Distinction in English from Dartmouth College, where he was a Senior Fellow and a member of Phi Beta Kappa, and an MD from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA. In 1992, Doug was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations.

In 1996, Doug joined Cytotherapeutics, in Providence, RI. As Medical Director, he oversaw various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1997, he was appointed Program Executive at Vertex Pharmaceuticals, Inc., in Cambridge, MA, where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair, oversaw an international research collaboration, and was responsible for identifying strategic market and technology opportunities in multiple arenas.

At Flagship, Doug has led investments in CombinatoRx, Tetraphase Pharmaceuticals, Alvine Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios Pharmaceuticals, Seventh Sense Biosystems, and Avedro. He is a co-founder of Flagship portfolio company Ensemble Therapeutics, Permeon Biologics, and ModeRNA Therapeutics. He currently serves on the Board of Directors of Tetraphase Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios, Selecta Biosciences, Avedro, Seventh Sense Biosystems, and Resolvyx Pharmaceuticals, and is an Observer on the Board of Directors of Alvine Pharmaceuticals. He formerly served on the Board of Directors of AVEO Pharmaceuticals (NASDAQ: AVEO), CombinatoRx, CGI and Morphotek. Doug is a member of the Scientific Advisory Board of the Spinal Muscular Atrophy Foundation, the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics, the Scientific Advisory Board of the Massachusetts Life Sciences Center, and serves on the Board of Directors of the Birch Rock Camp in Waterford, ME.

John Cox is the Nomura Professor of Finance and a Professor of Finance at the MIT Sloan School of Management. A leading authority on corporate finance and finance theory, Cox has developed an inter-temporal financial model broad enough to include the fundamental underlying forces affecting financial markets. Using this framework, he has devised a theory of the term structure of interest rates. His bond-pricing model is widely used on Wall Street. In the field of contingent claims, Cox has examined the foundations of option valuation. His principle of risk-neutral valuation has become an essential feature of subsequent work on derivatives. He also has developed a simple numerical scheme for valuing American options that is used by most firms dealing in equity derivatives. For many years, his book, Options Markets, has been a leading text in the field. In the area of dynamic investment strategies, he has studied how best to manage a portfolio over time to meet specific objectives. His work also has examined how the length of the planning horizon affects optimal behavior. Cox holds a BA in economics from Louisiana State University and a PhD in business and applied economics from the University of Pennsylvania.

Douglas Criscitello is a Managing Director at Grant Thornton LLP where he assists the U.S. government in its active role in the financial marketplace both as regulator and participant in the capital marketplace. His experience spans 27 years in government, banking and management consulting. Before joining Grant Thornton, Doug was the Senate-confirmed CFO at the Department of Housing & Urban Development (HUD), appointed by President Obama, where he directed the execution of HUD’s financial management program, including analytically focused work involving the Department’s credit and insurance programs. Before HUD, his prior position in the public sector was as the founding Director of the New York City Independent Budget Office, a municipal government agency designed to provide nonpartisan, objective research and analysis of NYC’s budget. Prior to IBO, Doug spent a decade in the federal government focused on credit programs and budgeting as CFO of the Small Business Administration and as a credit program analyst at the Office of Management and Budget. In the private sector, Doug worked for more than five years at JPMorgan’s Financial Institutions Group, where he provided operational, investment banking, and financial advisory services to U.S. government agencies and related entities.

Douglas A. Dachille, First Principles Capital Management. Please see steering committee members tab.

Ora Dar is the Head of the Life Sciences Sector at the Office of the Chief Scientist at the Israeli Ministry of Industry, Trade & Labor, and the Consultant for Biotechnology to the Chief Scientist. Being the head of the sector, Dr. Dar leads the team of experts recommending the granting of financial support by the Chief Scientist to projects in the field of Life Sciences. Dr. Dar is also responsible for defining and implementing tools and new programs required for supporting R&D in Life Sciences companies, and for enhancing the technology transfer between the Academia and the Industry. This has led to the initiation and maturation of several viable programs such as, funding academic applied research, dedicated scheme for biotechnology incubator(s), tracks enabling collaboration with global Life Sciences companies, tools for upgrading infrastructures, and a special government backed Bio Funds. Previously she spent 16 years in academic research (mostly at the Weizmann Institute of Science), several years in the industry, and 10 years as a consultant to venture capital and investment firms as well as foreign funds and international R&D programs. Dr. Dar is a medical sciences graduate of the Hebrew University of Jerusalem and holds a Ph.D. from the University of London, UK (St. Mary’s Hospital Medical School, Imperial College of Science, Technology and Medicine).

O. Prem Das is the Chief Research Business Development Officer at Dana-Farber Cancer Institute (DFCI) and heads DFCI’s Office of Research and Technology Ventures. He is also responsible for growing DFCI’s research business development, working with DFCI faculty and Integrative Research Centers to enhance relationships with the corporate sector, generating sponsored research agreements, and commercializing DFCI discoveries. Prem’s background includes managing academic technology transfer offices, biotechnology business development, and basic research. Most recently, Prem was involved in creating start-up companies and consulting for biotechnology companies and the NCI. Prior to this, he served as Senior Vice President for Technology Alliances at Praecis Pharmaceuticals, where his business development efforts led to the acquisition of the company by Glaxo-Smith Kline. Prem also has directed the Office of Technology Licensing at Harvard Medical School and the Office of Industrial Affairs at Memorial Sloan-Kettering Cancer Center. In addition, he has worked at Cadus Pharmaceuticals and co-founded Heartland BioTechnologies. During his academic research career, Prem published in various areas of biology. He received his MSc in chemistry from IIT/Kanpur in India and his PhD in biological chemistry from MIT.

Sanjiv Das is Professor of Finance at Santa Clara University’s Leavey School of Business, and previously held faculty appointments at Harvard Business School and UC Berkeley. He holds post-graduate degrees in Finance (Ph.D. from New York University) and Computer Science (M.S. from UC Berkeley), did undergraduate work in Accounting and Economics, and is also a qualified Cost and Works Accountant. In addition, he worked as Vice President for Citibank Asia. He is a senior editor of The Journal of Investment Management and co-editor of The Journal of Derivatives. Prior to being an academic, he worked in the derivatives business in the Asia-Pacific region. His current research interests include: the modeling of default risk, algorithms for harvesting financial information from the web, derivative pricing models, and portfolio theory. He has published more than 60 articles in academic journals.

Alan F. Eisenberg serves as Executive Vice President for Emerging Companies & Business Development at the Biotechnology Industry Organization (BIO). In this role, Eisenberg manages and directs BIO’s services and advocacy efforts for BIO’s 650+ emerging companies, which comprise approximately 90% of BIO’s membership. This includes tax, capital formation, financial services, and selected health policy development and advocacy, BIO’s global portfolio of investor and partnering events, industry research and analysis, and BIO’s affinity purchasing program enrolling over 2,000 companies.

Previously at BIO, Eisenberg served in other senior leadership roles, including responsibilities for BIO’s communications function, as well as state government relations, Board operations, and BIO’s political action committee. From 2001 through 2004, Eisenberg served as Health and Economics Policy Advisor to BIO CEO Jim Greenwood during his tenure in Congress. In this role, Eisenberg was extensively involved in the enactment of several public laws including the Medical Device User Fee and Modernization Act (P.L. 107-250), the Best Pharmaceuticals for Children Act (P.L. 107-109), as well as key provisions of the Medicare Modernization Act (P.L.108-173). Prior to that, Eisenberg briefly served on the staff of the Senate Health, Education, Labor and Pensions Public Health Subcommittee as Health Policy Advisor and also was a legislative assistant for Congressman John Shadegg (R-AZ).

Before coming to Washington, Eisenberg spent four years with Ford Motor Company in Dearborn, MI, as a research economist and finance manager in manufacturing. As an economist, Eisenberg was responsible for conducting and overseeing the development of analyses relating to a variety of energy, regulatory and tax matters. Eisenberg holds a Master in Public Policy degree from Harvard University (Kennedy School of Government), a Master of Science in Finance degree from George Washington University, and a Bachelor of Science degree from Union College.

Dr. Williams Ettouati received his Doctorât d’ État en Pharmacie from Université René Descartes, Paris V and a Master Arts Biology, University of California, Santa Barbara. He is currently Director, Industry Relations and Development and Health Sciences Associate Clinical Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) at the University of California San Diego. Dr. Ettouati’s role at the Skaggs School of Pharmacy is to develop and secure strategic collaborations, ranging from drug discovery to corporate sponsored fellowships for Pharm.D. students with pharmaceutical and biotechnology companies. Before joining the Skaggs School of Pharmacy and Pharmaceutical Sciences, Dr. Ettouati spent twenty years in the pharmaceutical and biotechnology industry.

Dr. Ettouati has proven and extensive experience encompassing multiple functional disciplines in pharmaceutical executive management, in areas such as business development, licensing, marketing and new product planning strategy in biotech and pharmaceutical companies. Dr. Ettouati served as CEO, President & Co-Founder, Director, GeneProt and Ceptyr early-stage drug discovery biotech companies. In addition, he was Chief Business Officer for several biotech firms such as Hawaii Biotech, responsible for all partnering activities; Vice President Business Development for Syrrx, Aurora/Vertex, Vice President Marketing at DepoTech and product management at Syntex (now Roche), ICI (now Astra-Zeneca). Finally, Dr. Ettouati had an established pharmaceutical consulting practice with many private and public clients.

Oliver Fetzer is the President and Chief Executive Officer of Cerulean Pharma Inc. He has served as the chief executive officer since 2009. Prior to joining Cerulean, he was senior vice president, corporate development and research and development at Cubist Pharmaceuticals (NASDAQ: CBST). While at Cubist, his responsibilities included corporate development, business development, drug discovery research, non-clinical development, clinical development, chemical development, medical affairs, and program management. Previously, Oliver served as a managing director and partner at the Boston Consulting Group (BCG) in the firm’s healthcare practice, where he was responsible for projects in strategy, operational effectiveness, and mergers and integration. He worked with clients both in and outside of healthcare while he was stationed at the BCG offices located in Boston, Auckland, and Munich. While at BCG, Oliver also led the associate recruiting effort for the Boston office and was a member of the Career Development Committee. Early in his career, Oliver worked at Bayer AG, where he was involved in chemistry and pharmaceutics.

Oliver is presently a director of Auxilium Pharmaceuticals (NASDAQ: AUXL), Tecan Group AG (SWX: TECN), and Cerulean Pharma. He earned his B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an M.B.A. from Carnegie Mellon University.

H. Gifford Fong is President of Gifford Fong Associates, a firm specializing in fixed income, derivative product and asset allocation analysis. Independent valuation, model validation and portfolio strategy analysis are areas of emphasis. He is a graduate of the University of California where he earned his B.S., M.B.A. and J.D. (law).

Mr. Fong is the editor of the Journal Of Investment Management (JOIM); founder of the JOIM Conference Series; member of the Advisory Group of the University of California Regents Committee on Investments; member of the Corporation Visiting Committee for the MIT Sloan School of Management; member of the North American Executive Board of the MIT Sloan School; member of the Advisory Board of the Finance Faculty of the MIT Sloan School; founding sponsor, member of the Steering Committee of the Masters In Financial Engineering Program at the University of California at Berkeley; member, Haas Hall of Fame, Haas School of Business, University of California at Berkeley; and member of the Board of Trustees, University of California, Berkeley Foundation; former editor of the Financial Analysts Journal; former member of the Board of Directors and Program Chairman of the Institute for Quantitative Research in Finance; former Vice Chair and member of the Research Committee of the Research Foundation of the CFA Institute and a contributor to a number of professional books and journals.

In addition, Mr. Fong is co-author of “Fixed-Income Portfolio Management,” a book published by Dow Jones-Irwin, co-author of “Advanced Fixed Income Portfolio Management, The State of the Art,” a book published by Probus Publishing, editor of “The Credit Market Handbook: Advanced Modeling Issues,” a book published by Wiley Finance, editor of “The World of Hedge Funds: Characteristics and Analysis” and “The World of Risk Management,” books published by World Scientific. He is also the author of numerous professional journal publications. Mr. Fong has received a number of honors, including the Institute for Quantitative Research in Finance Award and the Financial Analysts Journal Graham and Dodd Award of Excellence. He also is on a number of boards of directors of non-related companies and non-profit institutions.

Dr. Ansbert Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM’s effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. MPM Capital is one of the world’s largest dedicated investors in the life sciences. With committed capital under active management in excess of $2.0 billion, MPM is uniquely structured to invest globally in healthcare innovation through its BioVentures family of venture capital funds.

Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and Harvard University. At the German Cancer Research Center, Dr. Gadicke cloned the first cDNAs of HPV16 and 18 in Prof. Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Dr. Gadicke has published in leading scientific publications including Nature and Cell.

Dr. Gadicke is a Director of Radius Health. He previously served as a Director of BioMarin (BMRN); Biovitrum (Stockholm:BVT); Chiasma; Coelacanth; Idenix (IDIX); Kourion (acquired by VIAC); MediGene (Frankfurt:MDG); Omrix (OMRI); Pharmasset, Inc.(VRUS); PharmAthene (PIP); Solasia Pharma K.K., Tokyo; Transform (acquired by JNJ), Verastem, Inc. (VSTM); and ViaCell (VIAC). He is a member of the Board of Fellows of Harvard Medical School.

Clifford Gibbons is a senior international policy advisor that provides counsel and advocacy to help global companies navigate the intersections of business and government. His firm, Gibbons & Co., represents leading universities and cancer centers in Washington to develop Federal funding for large scale cancer research and drug development. Gibbons established the National Functional Genomics Center (NFGC) in 2002 to discovery early detection molecular signatures for cancers and to accelerate to clinical practice personalized cancer therapeutics. Supported by the U.S. Department of Defense, the NFGC has developed over $120 million in translational cancer research funding. These applied research funds are supported with multi-million dollar research grants from NIH, NCI, foundations and venture capital funding.

Michael Goldberg graduated Summa Cum Laude with an Hon. B.Sc. from the University of Toronto, where he was recognized as a University of Toronto Alumni Association Scholar and “Leader of Tomorrow”. He received an M.Phil. from the University of Cambridge prior to completing his Ph.D. at the Massachusetts Institute of Technology. He received post-doctoral training in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. In 2012, Dr. Goldberg became an assistant professor of Microbiology and Immunobiology at Harvard Medical School and in the Department of Cancer Immunology & AIDS at Dana-Farber Cancer Institute.His laboratory’s research interests include cancer immunotherapy and the creation of innovative platforms for drug development and delivery by combining the tools of chemistry, engineering, immunology, molecular biology, and nanotechnology.

Daniel Goroff is a Program Director at the Alfred P. Sloan Foundation who is especially interested in economics, finance, mathematics, the scientific and technical work force, and education. He is also Professor Emeritus of Mathematics and Economics at Harvey Mudd College in Claremont, California, where he previously served as Vice President for Academic Affairs and Dean of the Faculty.

Goroff earned his B.A.-M.A. degree in mathematics summa cum laude at Harvard as a Borden Scholar, an M.Phil. in economics at Cambridge University as a Churchill Scholar, a Masters in mathematical finance at Boston University, and a Ph.D. in mathematics at Princeton University as a Danforth Fellow. His first faculty appointment was at Harvard University in 1983. During over two decades there, he rose to the rank of Professor of the Practice of Mathematics while also serving as Associate Director of the Derek Bok Center for Teaching and Learning and as a Resident Tutor at Leverett House.

A 1988 Phi Beta Kappa Teaching Prize winner, Goroff taught courses in the mathematics, economics, physics, history of science, and continuing education programs at Harvard. He was also the founding director of a Masters Degree Program in “Mathematics for Teaching” offered through the Harvard Extension School. Beginning with the international distance education courses he developed using audiographics conferencing over twenty years ago, and continuing through his most recent online course called “Decisions, Games, and Negotiations,” Goroff has been an educational innovator throughout his teaching career.

In pursuing his work on nonlinear systems, chaos, and decision theory, Daniel Goroff has held visiting positions at the Institut des Hautes Etudes Scientifiques in Paris, the Mathematical Sciences Research Institute in Berkeley, Bell Laboratories in New Jersey, and the Dibner Institute at MIT.

In 1994, Goroff was elected to a three-year term on the Board of Directors of the American Association for Higher Education. During 1996-97, he was a Division Director at the National Research Council in Washington, and during 1997-98, Goroff worked for the President’s Science Advisor at the White House Office of Science and Technology Policy.

As Director of the Joint Policy Board for Mathematics from 1998 to 2001, Daniel Goroff was called to testify about educational and research priorities both by the House and again by the Senate during the 106th Congress. He also testified before the 109th Congress. A former Chair of the U.S. National Commission on Mathematics Instruction at the National Research Council, he was co-director with Richard Freeman of the Scientific and Engineering Workforce Project based at the National Bureau of Economic Research. The book they edited together is called Scientific and Engineering Careers in the United States.

Jonathan Gruber is a Professor of Economics at the Massachusetts Institute of Technology, where he has taught since 1992. He is also the Director of the Health Care Program at the National Bureau of Economic Research, where he is a Research Associate. He is an Associate Editor of both the Journal of Public Economics and the Journal of Health Economics. In 2009 he was elected to the Executive Committee of the American Economic Association. He is also a member of the Institute of Medicine, the American Academy of Arts and Sciences, and the National Academy of Social Insurance.

Dr. Gruber received his B.S. in Economics from MIT, and his Ph.D. in Economics from Harvard University. Dr. Gruber’s research focuses on the areas of public finance and health economics. He has published more than 140 research articles, has edited six research volumes, and is the author of Public Finance and Public Policy, a leading undergraduate text, and Health Care Reform, a graphic novel. In 2006 he received the American Society of Health Economists Inaugural Medal for the best health economist in the nation aged 40 and under.

During the 1997-1998 academic year, Dr. Gruber was on leave as Deputy Assistant Secretary for Economic Policy at the Treasury Department. From 2003-2006 he was a key architect of Massachusetts’ ambitious health reform effort, and in 2006 became an inaugural member of the Health Connector Board, the main implementing body for that effort. In that year, he was named the 19th most powerful person in health care in the United States by Modern Healthcare Magazine. During the 2008 election he was a consultant to the Clinton, Edwards and Obama Presidential campaigns. During 2009-2010 he served as a technical consultant to the Obama Administration and worked with both the Administration and Congress to help craft the Patient Protection and Affordable Care Act. In 2011 he was named “One of the Top 25 Most Innovative and Practical Thinkers of Our Time” by Slate Magazine.

Peter Hancock is an Executive Vice President of AIG and was named Chief Executive Officer of AIG’s global property casualty business in March 2011, when the division was reorganized into two major global groups, commercial and consumer. Mr. Hancock joined AIG in 2010 with responsibility for Finance, Risk and Investments. Mr. Hancock has spent his entire career in financial services, including 20 years at J.P. Morgan, where he established the Global Derivatives group, ran the Global Fixed Income business and Global Credit portfolio, and served as the firm’s Chief Financial Officer and Chief Risk Officer. He co-founded and served as President of Integrated Finance Limited, an advisory firm specializing in strategic risk management, asset management, and innovative pension solutions. He joined AIG from KeyCorp, where he was Vice Chairman, responsible for Key National Banking. Mr. Hancock was raised in Hong Kong and later attended Oxford University where he earned his Bachelor of Arts degree in Politics, Philosophy and Economics.

Gigi Hirsch, M.D., brings nearly 30 years of clinical and business experience in the healthcare industry to MIT’s Center for Biomedical Innovation (CBI). She joined CBI in 2006 and became Executive Director in 2007. Her current efforts at CBI are focused largely on leading New Drug Development Paradigms (NEWDIGS), a unique collaboration focused on transforming the global healthcare innovation system to deliver new, better, affordable therapeutics to the right patients faster.

Dr. Hirsch has held a number of leadership roles that leverage her broad clinical background (internal medicine, emergency medicine, and psychiatry) along with her passion for innovation, entrepreneurship, and improving patient care. Prior to joining CBI, she served as Director of Academic and Professional Relations at Millennium Pharmaceuticals, and was founder and CEO of a boutique entrepreneurial venture (MD IntelliNet) that spun out of an academic research and consulting firm that she founded in partnership with Boston’s Beth Israel Hospital. She completed her residency training in Internal Medicine and Psychiatry, and practiced full-time Emergency Medicine for nearly five years at Brigham and Women’s Hospital in Boston. She was an Instructor in Psychiatry at Harvard Medical School from 1992-1997. She previously held appointments in Internal Medicine at Harvard Medical School and Brown University after receiving her medical degree at the University of Cincinnati in 1981.

John Hull is the Maple Financial Professor of Derivatives and Risk Management at the Joseph L. Rotman School of Management, University of Toronto. He is an internationally recognized authority on derivatives and risk management. He was, with Alan White, one of the winners of the Nikko-LOR research competition for his work on the Hull-White interest rate model and was in 1999 voted Financial Engineer of the Year by the International Association of Financial Engineers. He has acted as consultant to many North American, Japanese, and European financial institutions. He has written three books “Risk Management and Financial Institutions” (now in its second edition), “Options, Futures, and Other Derivatives” (now in its eighth edition) and “Fundamentals of Futures and Options Markets” (now in its seventh edition). The books have been translated into many languages and are widely used in trading rooms throughout the world, as well as in the classroom. He has won many awards for teaching and research, including University of Toronto’s prestigious Northrop Frye award.

Alan Jakimo, a senior counsel in the New York office of Sidley Austin LLP, works on technology-oriented transactions in the life science and information science industries. His experience encompasses the interplay among finance, technology development, and intellectual property licensing in a broad range of transactions in the Americas, Asia, and Europe. He also serves as a Special Professor of Law at Hofstra Law School, where he teaches a course on the influence of law and regulation on the discovery, development, and commercialization of regulated medical products.

Robert Jarrow, is a Professor at Cornell University and director of research at Kamakura Corporation. He is a creator of the Heath-Jarrow-Morton model, the forward price martingale measure, and reduced form credit risk models. His research was the first to distinguish forward/futures prices and study option pricing with market manipulation. He has been the recipient of numerous prizes and awards including the CBOE Pomerance Prize for Excellence in Options Research, the Graham and Dodd Scrolls Award, the Bernstein Fabozzi/Jacobs Levy Award, and the 1997 IAFE/SunGard Financial Engineer of the Year. He is on the advisory board of Mathematical Finance – a journal he co-started in 1989. In 2009 he was awarded Risk Magazine’s Lifetime Achievement Award. He is included in both the Fixed Income Analysts Society Hall of Fame and Risk Magazine’s 50 member Hall of Fame. He has written five books and has over 180 academic journal publications. His newest book, entitled Derivative Securities, Financial Markets, and Risk Management, is now available for sale.

Thomas Kalil is currently serving as the Deputy Director for Policy for the White House Office of Science and Technology Policy and Senior Advisor for Science, Technology and Innovation for the National Economic Council.

Mr. Kalil is on leave from UC Berkeley, where he was Special Assistant to the Chancellor for Science and Technology at UC Berkeley. In 2007 and 2008, Mr. Kalil was the Chair of the Global Health Working Group for the Clinton Global Initiative. He was also a Senior Fellow with the Center for American Progress. Previously, Mr. Kalil served as the Deputy Assistant to President Clinton for Technology and Economic Policy, and the Deputy Director of the White House National Economic Council.
Thomas Kalil is currently serving as the Deputy Director for Policy for the White House Office of Science and Technology Policy and Senior Advisor for Science, Technology and Innovation for the National Economic Council.

Mr. Kalil is on leave from UC Berkeley, where he was Special Assistant to the Chancellor for Science and Technology at UC Berkeley. In 2007 and 2008, Mr. Kalil was the Chair of the Global Health Working Group for the Clinton Global Initiative. He was also a Senior Fellow with the Center for American Progress. Previously, Mr. Kalil served as the Deputy Assistant to President Clinton for Technology and Economic Policy, and the Deputy Director of the White House National Economic Council.

Jeb Keiper is Vice President (VP), Business Development for GSK Oncology, a member of the Oncology Executive, R&D, Commercial, and Medical teams as well as the Business Development Leadership Team. Jeb is responsible for defining and executing the business development strategy for GSK Oncology, including in‐licensing transactions, acquisitions, strategic alliances, academic research relationships, alliance management and competitive intelligence. Jeb is also the Senior Site Leader for the Upper Providence R&D campus (1500 staff) with responsibilities on long term facility and workforce planning, community outreach and employee engagement. Jeb joined GSK in 2005 as RADEX Secretary for R&D Chairman Moncef Slaoui. In 2008, he moved to Worldwide Business Development (WWBD) where he has held multiple roles prospecting early- and late-stage licensing opportunities, leading the R&D-based divestment program, and helping to establish the WWBD Transactions Centre of Excellence for GSK as Head of Acquisitions and Divestments. Prior to joining GSK, Jeb worked in business development at Boston-based TransForm Pharmaceuticals (bought by J&J in 2005 for $230 million), as well as for McKinsey & Company, a management consultant firm serving pharma and biotech clients. Jeb began his career at Pfizer Central Research as a chemist. He received four degrees from the Massachusetts Institute of Technology (MIT) in Chemistry, two in Chemical Engineering, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with Harvard Medical School.

Manolis Kellis is an Associate Professor of Computer Science at MIT, a member of the Computer Science and Artificial Intelligence Laboratory and of the Broad Institute of MIT and Harvard, where he directs the MIT Computational Biology Group (compbio.mit.edu). His group has recently been funded to lead the integrative analysis efforts of the modENCODE project for Drosophila melanogaster, and also for integrative analysis of the NIH Epigenome Roadmap Project. He has received the US Presidential Early Career Award in Science and Engineering (PECASE) for his NIH R01 work in Computational Genomics, the NSF CAREER award, the Alfred P. Sloan Fellowship, the Karl Van Tassel chair in EECS, the Distinguished Alumnus 1964 chair, and the Ruth and Joel Spira Teaching Award in EECS. He was recognized for his research in genomics as one of the top young innovators under the age of 35 by Technology Review Magazine, one of the principal investigators of the future by Genome Technology magazine, and one of three young scientists representing the next generation in biotechnology by the Boston Museum of Science. He obtained his Ph.D. from MIT, where he received the Sprowls award for the best doctorate thesis in computer science, and the first Paris Kanellakis graduate fellowship. Prior to computational biology, he worked on artificial intelligence, sketch and image recognition, robotics, and computational geometry, at MIT and at the Xerox Palo Alto Research Center.

Robert Langer, MIT. Please see steering committee members tab.

Pablo Legorreta, Royalty Pharma. Please see steering committee members tab.

Bruce N. Lehmann is a professor of finance and economics in the Graduate School of International Relations and Pacific Studies of the University of California, San Diego. Prior to joining IR/PS in 1992, he was on the faculty of the Department of Economics and the Graduate School of Business at Columbia University for eleven years. Professor Lehmann is a specialist in financial economics, with expertise in the pricing of capital assets, their volatility, and the markets in which they trade. His main research interests include empirical tests of asset pricing models, the analysis of short-run stock price fluctuations, and the microstructure of securities markets, with recent emphasis on the behavior of Japanese financial markets. Lehmann is the author of numerous articles in leading scholarly journals, including the Journal of Finance; the Journal of Financial Economics; Macroeconomic Dynamics; the Quarterly Journal of Economics; and the Journal of Econometrics. He is also the author of the entry “Empirical Testing of Asset Pricing Models” in the New Palgrave Dictionary of Money and Finance. Lehmann is founding co-editor of the Journal of Financial Markets and has served as associate editor of the Review of Financial Studies and the Review of Quantitative Finance and Accounting. He has served as a director of the Western Finance Association, a member of the Scientific Advisory Board of Investment Technology Group, Inc. and on the boards of directors of First Boston Investment Funds, Inc. and of BEA Associates, Inc. Lehmann currently serves on the Investment Advisory Board of the University of California Retirement System and Endowment and on the Investment Committee of the UC San Diego Foundation. He has earned many honors and distinctions: he was a Batterymarch Fellow, the most prestigious award given to scholars in finance; an Olin Fellow at the National Bureau of Economic Research; and a National Fellow at the Hoover Institution on War, Revolution and Peace at Stanford University. He is the only person to receive all three distinctions. He is currently actively exploring early stage drug development based on the megafund concept.

He earned his A.B. in economics and history magna cum laude from Washington University and his M.A. and Ph.D. degrees in economics from the University of Chicago.

J. Leonard Lichtenfeld, M.D., M.A.C.P., deputy chief medical officer for the American Cancer Society, is responsible for directing the Society’s Cancer Control Science department. This group of internationally recognized experts focuses on the prevention and early detection of cancer, as well as emerging science and trends in cancer. The department is responsible for producing the Society’s widely recognized guidelines for the prevention and early detection of cancer, including the role of nutrition and physical activity. Dr. Lichtenfeld is also recognized as a resource both within and outside the Society for his expertise in oncology and medical affairs. He serves as a liaison for the Society with many professional and public organizations, and is a frequent spokesperson on behalf of the Society on a variety of cancer-related subjects.

A board-certified medical oncologist and internist who was a practicing physician for more than 19 years, Dr. Lichtenfeld has long been active in medical affairs on a local, state, and national level. He is active in several state and national medical organizations. He is a member of the Relative Value Update Committee (RUC) of the AMA, which works with the Centers for Medicare and Medicaid Services to update the Medicare physician fee schedule (RBRVS). Dr. Lichtenfeld is a member of CMS’ Medicare Evidence Development and Coverage Advisory Committee. He has a long-standing interest in legislative and regulatory issues, and serves on several national committees focused on the quality of medical care and the role of health information technology in health care delivery.

Dr. Lichtenfeld is a graduate of the University of Pennsylvania and Hahnemann Medical College (now Drexel University College of Medicine) in Philadelphia. His postgraduate training was at Temple University Hospital in Philadelphia, Johns Hopkins University School of Medicine and the National Cancer Institute in Baltimore. He is a member of Alpha Omega Alpha, the national honor medical society. Dr. Lichtenfeld has received several awards in recognition of his efforts on behalf of his colleagues and his professional activities. He has been designated a Master of the American College of Physicians in acknowledgement of his contributions to internal medicine.

Andrew W. Lo is the Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management and the Director of MIT’s Laboratory for Financial Engineering. His research is focused on the fundamental aspects of investments and financial markets, including measuring illiquidity risk in hedge-fund returns, the growth of systemic risk in the hedge-fund industry, and most recently, evolutionary and neurobiological models of individual risk preferences and financial markets. He has published numerous articles, and is a co-author of The Econometrics of Financial Markets, A Non-Random Walk Down Wall Street, and The Evolution of Technical Analysis, and author of Hedge Funds: An Analytic Perspective. He is currently a co-editor of the Annual Review of Financial Economics and an associate editor of the Financial Analysts Journal, the Journal of Portfolio Management, and the Journal of Computational Finance. He is also a research associate of the National Bureau of Economic Research, a member of FINRA’s Economic Advisory Board, the OFR Financial Research Advisory Committee, the CME Group Competitive Markets Advisory Council, the Consortium for Systemic Risk Analytics Academic Advisory Board, and founder and chief investment strategist of AlphaSimplex Group, LLC, an investment advisory firm based in Cambridge, Massachusetts.

Deborah J. Lucas is the Sloan Distinguished Professor of Finance at MIT’s Sloan School of Management. Her recent research has focused on the problem of measuring and accounting for the cost and risk of government financial obligations. Her published papers cover a wide range of topics including the effect of idiosyncratic risk on asset prices and portfolio choice, dynamic models of corporate finance, financial institutions, and monetary economics.

Previous appointments include assistant director at the Congressional Budget Office from 2009-2011; Donald C. Clark Professor of Finance at Northwestern University’s Kellogg School of Management from 1996-2009; chief economist at the Congressional Budget Office from 2000 to 2001; senior economist at the Council of Economic Advisers from 1992 to 1993; and member of the Social Security Technical Advisory Panels of 1999-2000 and 2006–2007. She is a co-editor of the Annual Review of Financial Economics, and a past co-editor of the Journal of Money, Credit and Banking. She is the co-organizer of the group Capital Markets and the Economy at the NBER, and a past director of the American Finance Association. She is an elected member of the National Academy of Social Insurance, a research associate of the NBER, and has served as a director on several corporate and non-profit boards. She received her BA in economics, an MA, and a PhD in economics from the University of Chicago.

Usama Malik is a Senior Leader responsible for shaping, building & growing the global Governance, Culture and Leadership Solutions business at LRN (helping companies innovate in how they do business). Prior to LRN, Mr. Malik was a Senior Manager with Bridgewater Associates.

Previously, Mr. Malik was the Vice President and Chief Innovation Officer at Pfizer Inc. In this role he was focused on creating a sustaining culture of Innovation within the company, while investing in transformational & disruptive ideas (through $100M venture fund) that enhanced existing revenues or generated new ones (through creation of new healthcare business models), improved the company’s cost structure or reduced business risk. Mr. Malik also lead Pfizer’s strategy for diversification across all of the Pfizer Diversified Businesses (i.e. ex-Pharma businesses — $~10B revenue). In this role He provided strategic leadership to grow existing diversified businesses, while driving the overall diversification strategy and approach for Pfizer Inc. Prior to these roles, He was a senior member of Pfizer’s Corporate Strategy group, responsible for managing the $68B Pfizer-Wyeth integration, designing and developing a new R&D model (BBC), and developing the company’s Biosimilars strategy among other large initiatives.

Prior to Pfizer, Mr. Malik was a leader in Booz & Company’s healthcare and life science strategy consulting practice. In this role he consulted to the CEOs and executive teams of large Pharma, Payor, Diagnostic Services, HIT, and Hospital companies in North America and Europe on the topics of growth strategy, innovation, international expansion, M&A, and business and operating model transformation.

Before embarking on a healthcare career, Usama spent 7 years as a management consultant, strategic planner, and product manager in the telecommunications industry. His key focus was on creating new businesses and investing in disruptive technologies for large telecom providers around the world.

Parag Mallick is an Assistant Professor in the Department of Radiology at the Stanford School of Medicine. He is also a member of the Canary Center at Stanford for Cancer Early Detection , Bio-X, and Molecular Imaging Program at Stanford (MIPS). Dr. Mallick received his BS in computer science and biochemistry from Washington University in St. Louis and his PhD from the University of California, Los Angeles, in chemistry and biochemistry. He next moved to the state of Washington as a postdoctoral fellow at the Institute for Systems Biology in Seattle, where he researched clinical and quantitative mass spectrometry-based proteomics. Prior to joining to Stanford, Dr. Mallick was as an assistant professor in the Departments of Medicine and Biomedical Engineering at the University of Southern California (USC) and the director of clinical proteomics at the Center for Applied Molecular Medicine (CAMM), where he developed a systems biology and quantitative biology research group. He was also a visiting scientist at the Fred Hutchinson Cancer Research Center. At Stanford, his research focus is on systems biology approaches for the discovery of serologic and imaging biomarkers for cancer early detection in lung, pancreatic, prostate cancers, and lymphoma.

Nicholas F. Marko, MD is currently a fellow in neurosurgical oncology at the MD Anderson Cancer Center in Houston, Texas, after which he will assume the position of Director of Neurosurgical Oncology and Director of the Center for High-Performance Medical Computing at Geisinger Health System in Danville, Pennsylvania.

He continually works to build meaningful collaborations with creative thinkers from academia, healthcare- and non-healthcare-related industries, start-ups, and venture capital firms from the private, public, and government sectors. His research efforts and interests based on this theme are threefold. 1) the use of probabilistic, mathematical modeling and predictive analytic methods to develop tools capable of improving individualized risk prediction, informing more accurate medical and surgical decision-making processes, and developing data-driven, population-based screening and management strategies for common diseases. 2) Applying mathematical models to genomic and epigenomic data to improve our understanding of the fundamental biology of disease processes. This includes nonlinear and dynamical systems / chaotic modeling strategies for cancer, but it also includes integrating molecular and clinical data so that these types of analyses can be applied in a clinically-relevant fashion. 3) Using comparative effectiveness and econometric analysis strategies to study the costs and benefits of alternate management strategies in an effort to maintain high-quality patient care while optimizing the efficiency of healthcare delivery.

Dr. Marko’s clinical focus is the management of primary malignant and metastatic tumors of the brain and spinal cord. His specific academic medical interest centers around using applied mathematical techniques in conjunction with multimodality, integrated, large-scale databases to optimize the diagnosis and management of disease.

Dr. Marko completed his undergraduate and medical education at the George Washington University in Washington, DC. During this time he also spend one year as a Howard Hughes Institute Medical Student Fellow at The Institute for Genomic Research (TIGR) working with the computational biology and human gene expression groups. Dr. Marko completed his Neurosurgery residency training at the Cleveland Clinic in Cleveland, Ohio, following which he was the 2011-2012 American Association of Neurological Surgeons William P. VanWagenen Fellow. During that time he conducted research at Cambridge University in the United Kingdom, working at the interface of applied mathematics and translational oncology.

Frank McCormick, University of California, San Francisco. Please see steering committee members tab.

Robert C. Merton, MIT. <Please see steering committee members tab.

John C. McKew is the Acting Scientific Director of the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS) within the NIH. His responsibilities include developing the Therapeutics for Rare and Neglected Disease (TRND) program and the Bridging Interventional Development Gaps program (BrIDGs; former NIH-RAID program). Both of these programs focus on novel public/private partnerships to advance collaborative drug discovery projects through pre-clinical development into early clinical development. These collaborative projects are advanced using a combination of internal scientific resources as well as government contracts. Prior to joining the NIH, Dr. McKew held a Director level position at Wyeth Research in Cambridge, Massachusetts where he spent a total of 17 years. One role at Wyeth he held comprised leading a hit-to lead chemistry group supporting cardiovascular, musculoskeletal and metabolic disease therapeutic areas. Prior to that Dr. McKew spent 10 years working in the inflammation therapeutic area resulting in multiple compounds entering clinical evaluation. His research interests include rare and neglected disease research, medicinal chemistry, synthetic methodology, and tool compounds to probe biology. These interests have resulted in >25 publications, 10 Granted US Patents and multiple podium presentations. John also enjoys sharing his passion for science with others. This has prompted him to become course director and lecturer in GMS PM 881 “Drug Discovery and Development” a graduate level course in the Department of Pharmacology and Experimental Therapeutics which resulted in his appointment as an Adjunct Associate Professor Boston University School of Medicine. He has also taken an active role in the Northeastern Section of the American Chemical Society and has served as the Chair-Elect, Chair and the Immediate Past Chair. Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry. He completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.

Fiona Murray received BA and MA degrees in Chemistry from the University of Oxford before coming to the United States where she received her doctoral degree from Harvard University’s School of Engineering and Applied Sciences. Her research interests then moved away from the bench to the study of science commercialization, the organization of scientific research and the role of science in national competitiveness. After a short time on the faculty of Oxford’s Said Business School Fiona joined the MIT Sloan School of Management where she studies and teaches innovation and entrepreneurship including the campus-wide iTeams course developing “go-to-market” strategies for breakthrough innovations developed in MIT labs.

Murray works with a range of firms designing global organizations that are both commercially successful and at the forefront of science. These firms seek to leverage the ideas of a wide range of internal scientists. as well as external innovators accessed through traditional research contracts as well as “Open Innovation” mechanisms. Her recent engagements have focused on relationships that span the public and private sectors. She is particularly interested in new emerging organizational arrangements for effective commercialization of science including public-private partnerships, not-for profits, venture philanthropy, and university-initiated seed funding.

Murray is well-known for her academic work on how growing economic incentives – for examle intellectual property (IP), influence the rate and direction of scientific progress – particularly in the areas of genomics, stem cells, and mouse genetics. She is actively involved in U.S. and European policy debates over the appropriate use of IP and licensing in universities and more recently debates on when and when not to use patents to promoted discovery research in neglected diseases. Her research has been widely published in a diverse range of scientific and social science journals including Science, New England Journal of Medicine, Nature Biotechnology, Research Policy, Organization Science and the Journal of Economic Behavior & Organization.

Dr. Larry A. Nagahara is the Director of the Office of Physical Sciences-Oncology in the Center for Strategic Scientific Initiatives (CSSI), National Cancer Institute (NCI), where he coordinates and directs program and research activities related to expanding the role of the physical sciences in cancer research, including the Physical Sciences-Oncology Centers (PS-OC) Program. Previously, he served as the Nanotechnology Projects Manager for the NCI’s Alliance for Nanotechnology in Cancer program, for which he helped oversee the development of promising nano-based diagnostics and therapeutics projects and turned them into applications that will eventually benefit cancer patients. Dr. Nagahara also currently represents NCI on the Trans-NIH Nano Task Force, which is tasked to develop NIH-wide scientific and policy vision for nanotechnology, as well as NCI’s Project Scientist for the NIH’s Nanomedicine Development Centers and NIH’s Genes and Environment Initiative (GEI), Exposure Biology Program.

Dr. Nagahara has been actively involved in physical sciences and nanotechnology for over 15 years, most notably novel scanning probe microscopy development, carbon nanotube applications, molecular electronics, nanoenergy, and nanosensors. Before joining NCI, he was a Distinguished Member of the Technical Staff at Motorola and led their nanosensor effort. He is also currently an adjunct professor in the Department of Physics at Arizona State University and an Associate Editor of the IEEE Sensors Journal. Dr. Nagahara has published over 80 technical papers and 3 book chapters, and has 1 book pending as well as over 15 patents issued/filed in these fields. He is an American Physical Society (APS) Fellow and a Nano50 Awardee, and was a member of Motorola’s Scientific Advisory Board.

Joseph Naggar, is Head of Structured Products & Senior Portfolio Manager Partner, Executive Committee Member & Macro Committee Member of GoldenTree Asset Management. Mr. Naggar joined GoldenTree in 2007. He has spent his career in various capacities related to the CDO and correlation markets. Most recently, he served as a Managing Director in the Morgan Stanley Global Principal Credit Group where he was responsible for CLO trading and high yield loans. Previous to that, he ran global trading and US capital markets for CDOs at Morgan Stanley. Mr. Naggar led the CDO and correlation trading effort at Swiss Re Financial Products during the development of those markets in the early 2000s. Additionally, in the late 1990s, he served as a senior CDO structurer at both Morgan Stanley and Merrill Lynch. Mr. Naggar holds an MBA from the MIT Sloan School of Business with a concentration in Financial Engineering and a B.S. from the Pennsylvania State University in Mechanical Engineering through the University Scholars program.

Lita Nelsen, MIT. Please see steering committee members tab.

Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center.Please see steering committee members tab.

Dr. Robert O’Neill is currently the Senior Statistical Advisor to CDER in the Office of Translational Sciences in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Until June 2011 , Dr. O’Neill was the Director of the Office of Biostatistics which provides biostatistical and scientific computational leadership and support to all programs of CDER. Prior to October 1998 he was Director of the Office of Epidemiology and Biostatistics, responsible also for the post-market safety surveillance of new drugs. In 1989-1990, Dr. O’Neill was a visiting professor at the Department of Research, University Medical School, Basel, Switzerland, where he developed and presented numerous lectures and created a course series Topics in Therapy Evaluation and Review (TITER) for European pharmaceutical scientists, which was the model for the European Course In Pharmaceutical Medicine (ECPM), a degree granting graduate program. Dr. O’Neill was the ICH FDA topics leader for two guidances, E9 and E5. He is a fellow of the American Statistical Association (1985) and the Society for Clinical Trials (2013), a member of several professional societies, a past Member of the Board of Directors of the Society for Clinical Trials, the 2002 recipient of the Marvin Zelen Leadership Award in Statistical Science, and the 2004 Lowell Reed Lecture Awardee from the American Public Health Association.

Andy Palmer, has helped start, fund or found 25+ innovative companies in technology, health care and the life sciences. He was co-founder and founding CEO of Vertica Systems (acquired by HP). Andy has a strong interest in projects at the intersection of computer science and the life sciences. He was a member of the core startup team and the SVP and CIO at Infinity Pharmaceuticals (NASDAQ: INFI). As Global Head of Software and Data Engineering at Novartis Institutes for Biomedical Research, he built modern information systems for scientists to speed drug discovery and development. (BS, Bowdoin 1988; MBA, Tuck School of Business at Dartmouth, 1994)

John S. Parker, M.D.,FACS, FCCP Major General (Retired). Dr. Parker is a general and cardiothoracic surgeon. He is a Fellow and past member of the Board of Governors of the American College of Surgeons (FACS) and a Fellow in the American College of Chest Physicians (FCCP) and senior consultant to the ACCP disaster response committee. John is a graduate of Washington and Jefferson College, Georgetown University Medical School, and the Industrial College of the Armed Forces. Currently, Dr. Parker is the Senior Vice President, Corporate Development, Chief Medical Officer, Chairman of the Institutional Review Board, and Technical Fellow at Science Applications International Corporation (SAIC). Prior to joining SAIC, he was the commanding general, U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland, and Fort Detrick. He was responsible for medical research, product development, technology assessment, technology transfer, and rapid prototyping of medical materiel. John had the responsibility to oversea and mature the business operations of the Congressional Directed Medical Research Program (CDMRP).He has served as Special Assistant Secretary of Defense for Medical, Chemical and Biological Defense and was Deputy for Medical Systems, Office of the Assistant Secretary for Acquisition Logistics and Technology. Dr. Parker has served on a number of committees under the Academy of Sciences, National Research Council. He has had major leadership responsibilities in disasters such as; The Beirut bombing, Chernobyl (European Armed Forces Chairman), Berlin Disco bombing, USS Stark recovery and identification of victims, and the management and resolution of the Amerithrax incident. John serves as the Chairman Board of Scientific Advisors to The National functional Genomics Center

Dr. Parker serves as the Chairman of the National Biodefense Science Board. He was appointed by the Secretary of the Department of Health and Human Services.

Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School. He has been on the Harvard faculty for 23 years. During this time, he has taught MBA and executive level courses on technology and operations management, operations strategy, competitive strategy, product development, and the management of innovation. Professor Pisano’s research has examined technology strategy, the management of innovation, organizational learning, outsourcing, and the management of intellectual property. His research, teaching, and consulting on these issues span a range of science and technology based industries including aerospace, biotechnology and pharmaceuticals, health care, computers, software, telecommunications, and semiconductors.

Leslie Platt, JD is a nationally recognized life sciences and healthcare attorney and executive with over three decades of experience in a range of senior level legal, management, and consulting positions. After receiving his BA from George Washington University, he attended New York University School of Law to obtain his Juris Doctorate.

Over the years, Mr. Platt has advised Cabinet officers and top officials at federal agencies as well as senior executives and boards of directors of major domestic and international companies and nonprofit research organizations. He has managed large bioscience operating systems and projects involving complex financial, legal, and regulatory environments and challenges. He has structured and negotiated numerous agreements regarding the financing, conduct, and commercialization of biomedical research, the construction of research laboratories, and the protection, valuation, and transfer of associated intellectual property and technology.

Leslie Platt has conducted investigations and helped to resolve complex crises involving alleged abuse of human research volunteers, fraudulent reporting of scientific data, mishandling of restricted biological agents, misuse of intellectual property, and fraud and abuse in connection with federal healthcare grants and contracts. He has extensive practical experience in risk management, best practices, regulatory compliance, quality assurance and control and biosafety, information technology, and organizational governance for U.S. and transnational biotechnology, pharmaceutical, medical device, and healthcare organizations.

Mr. Platt has served as Board Chairman of the nonprofit BioJudiciary Project, and he chairs the Loudoun County, VA Science & Technology Cabinet. Leslie has taught legal and ethical aspects of bioscience management at George Mason University. He has authored a number of articles and is a frequent lecturer at industry conferences in the U.S. and around the world, and he has chaired the Loudoun County, VA Science and Technology Cabinet.

Mr. Platt has conducted investigations and helped to resolve complex crises involving alleged abuse of human research volunteers, fraudulent reporting of scientific data, mishandling of restricted biological agents, misuse of intellectual property, and fraud and abuse in connection with federal healthcare grants and contracts. He has extensive practical experience in risk management, best practices, regulatory compliance, quality assurance and control, biosecurity and biosafety, information technology, and organizational governance for U.S. and transnational biotechnology, pharmaceutical, medical device, and healthcare organizations.

Mr. Platt has served as Board Chairman of the nonprofit BioJudiciary Project, and he chairs the Loudoun County, VA Science & Technology Cabinet. Leslie has taught legal and ethical aspects of bioscience management at George Mason University. He has authored a number of articles and is a frequent lecturer at industry conferences in the U.S. and around the world.

Averill L. Powers is the Founding Managing Director of Syzygy Therapeutics. He spent five years as a Partner at Celtic Pharma and more recently at Celtic Therapeutics – global biotech private equity funds where he raised equity and debt capital, managed transaction and development professionals and structured, negotiated and executed deals. Mr. Powers has more than 20 years of experience in private equity, international mergers and acquisitions and corporate finance, including transactions for companies such as Centocor, Roche, Bristol-Meyers Squibb and Johnson & Johnson. Prior to Celtic, he spent five years at J.P. Morgan where he served as a permanent member of the firm’s Valuation Committee in Europe and as a participant on J.P. Morgan Capital’s Global Investment Committee. He began his career as a mergers and acquisitions attorney for Davis Polk & Wardwell and prior to that Cravath, Swaine & Moore. Mr. Powers has a B.A. from Columbia University and a J.D. from New York University School of Law.

Anna Protopapas has just been named President, Millennium, The Takeda Oncology Company. She retains her additional responsibilities as Executive Vice President of Business Development and a Corporate Officer for Takeda Pharmaceuticals. Anna assumed the leadership of Takeda’s business development efforts in October 2010 and led multiple initiatives to globalize Takeda, including the 2011 9.6 billion euro acquisition of Nycomed. Anna was formerly the Senior Vice President of Business Development and Strategy at Millennium where she helped engineer the $8.8 billion acquisition of the company by Takeda in 2008. She joined Millennium in 1997 and was instrumental in multiple strategic initiatives that moved the company from early stage genomics to fully integrated biopharmaceutical company. She is trained as a Chemical Engineer at Princeton and MIT and has an MBA from Stanford Business School.

Jon Retzlaff is the Managing Director of Science Policy & Government affairs for the American Association for Cancer Research (AACR). Before joining the AACR in 2010, Mr. Retzlaff led the health and biomedical practice for a government relations firm in D.C. Prior to that, he served as legislative director for the Federation of American Societies for Experimental Biology from 2004-2007. Additionally, he previously worked (from 1993-2004) for the National Institutes of Health (NIH), first as a program analyst within the NIH Office of the Director’s legislative office; then as a senior legislative advisor to the National Institute of Neurological Disorders and Stroke; and finally as the Executive Officer of the National Library of Medicine. During his time as an NIH employee, Mr. Retzlaff was “detailed” to the House (1998) and Senate (2000-2001) appropriations subcommittees on labor, health and human services, education and related agencies on health research funding issues, as well as within the Office of the Secretary for Legislation at the Department of Health and Human Services. He entered the Federal Government as a Presidential Management Intern in 1993 and completed a rotation in the Office of Senator Herb Kohl (D-Wis.) during his two-years of formal training. Mr. Retzlaff earned a Bachelor of Science degree from the University of Minnesota, a master’s degree in public administration from Indiana University and a master’s degree in business administration from the Massachusetts Institute of Technology.

Kira Rosoff is a Vice President in the Asset & Wealth Management division of Deutsche Bank. In this role, she advises individuals and institutions on wealth planning matters and investment decisions. Ms. Rosoff joined AWM from Alinda Capital Partners, where she raised capital from institutional investors both domestically and abroad. Prior to that, she worked in corporate strategy at Deutsche Bank US Private Wealth Management, building the group’s residential lending platform and managing client exposure during the financial crisis. She started her career in life sciences and technology consulting at Accenture. Ms. Rosoff holds an MBA from the MIT Sloan School of Business and an AB from Duke University. She is a member of the Special Projects Committee of Memorial Sloan-Kettering Cancer Center and the Duke University Young Alumni Development Council of New York.

Maya R. Said is the Head of Strategy, Science Policy & External Innovation for Sanofi. Dr. Said joined Sanofi in December 2011 after having spent seven years at The Boston Consulting Group (BCG) where she was a core member of BCG’s HealthCare and Strategy practice areas as well as BCG’s Strategy Institute. She has in depth knowledge of Sanofi where she was deeply involved as a BCG Principal in many of our projects in Transforming R&D since 2007. She most recently led the Genzyme R&D integration effort.
Prior to joining BCG, Dr. Said held research and teaching positions within the Department of Biological Engineering and the Department of Electrical Engineering & Computer Science (EECS) at the Massachusetts Institute of Technology (MIT) where she taught courses in the fields of signals and systems, digital signal processing, and quantitative physiology, and supervised research theses. She has also held research positions at the Woods Hole Oceanographic Institute, the Hewlett Packard Research Labs, and the Xerox Palo Alto Research Center.

Dr. Said is the author of numerous scientific and strategy publications including the first textbook chapter on Biological Signal Processing and an instructor’s manual on Discrete-Time Signal Processing. She is a member of the Eta Kappa Nu, Sigma Xi, Tau Beta Pi, and Phi Beta Kappa honor societies and has received a number of awards at BCG and at MIT including the Trust Award for client contributions, the Carlton E. Tucker award for teaching excellence, the Department Head Recognition Award for major contribution to the EECS Department at MIT, and the Burchard Scholar for excellence in Humanities and Social Sciences.

Dr. Said completed her undergraduate studies at the Massachusetts Institute of Technology (MIT) in 1998 and holds dual undergraduate degrees in Biology as well as Electrical Engineering & Computer Science with a minor in Economics. She did her graduate studies at MIT and earned a Master of Science in Toxicology in 2000, a Master of Engineering in Electrical Engineering and Computer Science in 2001 and a Doctor of Science in Electrical Engineering, Computer Science and Systems Biology in 2005.

David Schmittlein is the John C Head III Dean and Professor of Marketing at the MIT Sloan School of Management. His focus has been to broaden MIT Sloan’s global visibility, to work with the faculty in creating new high-quality management education programs, to develop enhanced educational opportunities for current students, and to develop and disseminate business knowledge that has impact and that will stand the test of time. He also has reached out to the many members of MIT’s alumni community to gain their valuable insights on MIT Sloan and management education.

Prior to his appointment at MIT Sloan, Schmittlein was the Ira A. Lipman Professor and Professor of Marketing at the Wharton School of the University of Pennsylvania from 1980 until 2007. He also served as Interim Dean during July 2007 and as Deputy Dean from 2000 to 2007, and was chair of the editorial board for Wharton School Publishing. His research assesses marketing processes and develops methods for improving marketing decisions. He is widely regarded for his work estimating the impact of a firm’s marketing actions, designing market and survey research, and creating effective communication strategies. Schmittlein has served as a consultant on these issues for numerous firms, including American Express, American Home Products, AT&T, Bausch & Lomb, Boston Scientific, Ford Motor Company, Gianni Versace S.p.A., Hewlett-Packard, Johnson & Johnson, Lockheed Martin, Pfizer, Revlon, Siebe PLC, the Oakland Raiders, The Quaker Oats Co., and Time Warner. His work has been published in leading journals in marketing, management, economics, and statistics. In addition, he has been an area editor for Marketing Science and a member of the editorial board for the Journal of Interactive Marketing, the Journal of Marketing Research, Marketing Letters, and Marketing Science.

Schmittlein serves on the International Advisory Board for Groupe HEC, the Governing Board of the Indian School of Business, the International Advisory Board of Lingnan (University) College of Sun Yat-sen University, and the Advisory Board for the School of Economics and Management of Tsinghua University. He has served on the World Economic Forum’s Global Agenda Council for Marketing and Branding. He has been a Visiting Professor in the Faculty of Economics at Tokyo University and a Distinguished Scholar in Residence at Washington University’s John M. Olin School of Business. Schmittlein has received awards for his research, his editorial work, and his teaching. His observations and research have been cited often in the popular press, including Advertising Age, Business 2.0, BusinessWeek, China.com, Computerworld, Fortune, NPR’s Marketplace, People’s Daily Online, Reuters,The ABC Evening News with Peter Jennings, The Economist, The Financial Times, The Los Angeles Times, The Philadelphia Inquirer, The New York Times, The Wall Street Journal, U.S. News & World Report, and USA Today. Schmittlein holds a BA in mathematics from Brown University and an MPhil and a PhD in business from Columbia University.

Azita Sharif founded Daedalus Software, Inc. and also serves as its Chief Executive Officer. Ms. Sharif serves as a Principal of Advent International Corporation. She serves as an Investment Professional at Triton Ventures. Prior to founding Daedalus Software, she worked in the Venture Capital Industry since 1995, as a Principal at Advent International Global Private Equity. Since 1995, she also serves as a Judge in the annual International Moot Corp. Business Plan Competition. Since 1997, she advises a number of seed stage start-ups on writing their business plans and in seeking venture funds. Before entering the Venture Capital Industry, she worked in the Semiconductor Industry with Praxair, Inc. both in Research & Development and in Sales and Marketing. She serves as a Director of the Executive Board of the Women’s Leadership Initiative at the JFK School of Government at Harvard University from 1996 to 2000. Ms. Sharif also served on the board of PMD, Inc. and Praxair Inc. and was on the HBS/McKinsey consulting team of National Foundation for Teaching Entrepreneurship (NFTE). She currently serves on the External Advisory Committee (EAC) of the Biomedical Engineering Department at the University of Texas at Austin (UT). She is a Member of Kauffman Fellows Class 1 and served her fellowship at Advent International , which she received the Special Recognition Award for customer service. Ms. Sharif earned her Bachelor’s degree in Mechanical Engineering and a Master’s degree in Mechanical and Biotechnology Engineering (with Honors) from The University of Texas at Austin. She holds a Master’s degree in International Law and Diplomacy from the Fletcher School and an M.B.A. from Harvard Business School.

Phillip A. Sharp, Institute Professor (highest academic rank) at MIT and faculty member of the Koch Institute for Integrative Cancer Research and Department of Biology, has made fundamental contributions to cancer biology and to understanding gene structure and regulation. Sharp’s seminal discovery of ‘split genes’ in eukaryotic cells and the associated mechanism of pre-mRNA splicing resulted in numerous awards and honors, including the Nobel Prize in Physiology or Medicine (1993), the Lasker Prize (1988), the Gairdner Foundation International Award (1986) and the 2004 National Medal of Science. In addition, he holds numerous honorary degrees from universities here and abroad and serves on many advisory boards for the government, academic institutions, scientific societies, and companies. He is elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the Royal Society of the UK. His MIT career spans over 39 years where he served as Director of the Center for Cancer Research (now the Koch Institute), Head of the Department of Biology and, later, was Founding Director of the McGovern Institute for Brain Research. A native of Kentucky, Dr. Sharp earned a B.A. degree from Union College, KY in 1966, and a PhD in chemistry from the University of Illinois, Champaign-Urbana in 1969. He did his postdoctoral training at the California Institute of Technology, where he studied the molecular biology of plasmids from bacteria in Professor Norman Davidson’s laboratory. Prior to joining MIT, he was Senior Scientist at Cold Spring Harbor Laboratory. He has published over 390 papers. In 1978 Dr. Sharp co-founded Biogen (now Biogen Idec) and in 2002 he co-founded Alnylam Pharmaceuticals.

Henry Shilling is a Senior Vice President with Moody’s Investors Service. With Moody’s since 1992, Henry is a member of the New York-based Global Managed Investments Group. He has responsibility for research, analysis and ratings of money market and bond mutual funds, various other pooled investment vehicles, pension funds, debt like instruments issued by closed-end funds as well as asset (fund) management companies. Earlier in his career he was a vice president with a firm specializing in tracking and evaluating the performance of mutual funds and an officer in the employee-benefit trust and asset management divisions of several large banks. Henry is the author of The International Guide to Securities Market Indices which was published in 1996 by International Publishing Corp., Chicago, Illinois. Also, a chapter entitled “Investing in Index Mutual Funds,” which he authored, appears in Frank Fabozzi’s Information Management Network’s Perspectives on Equity Indexing: Updated and Expanded Second Edition. He earned a B.A. in economics from Lehman College, City University of New York in 1971.

Gregory C. Simon is CEO of Poliwogg, a company formed under the JOBS Act to raise investments from accredited and non-accredited investors in health, community enterprises and high yield assets. Mr. Simon has held senior positions in both houses of Congress and the White House, been a senior strategy consultant to a number of international technology CEOs, led a national patient advocacy nonprofit he co-founded with Mike Milken, and has served as a senior executive at a large pharmaceutical corporation. He has developed a reputation as a visionary strategist, dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, drug research and development, and patient advocacy.

Most recently Mr. Simon was Senior Vice President for Patient Engagement at Pfizer, Inc. In that role he focused on engaging patients more productively in research and clinical trials and on helping Pfizer develop policies, practices, and medical solutions to improve health, happiness and productivity. Previously, from June 2009 to February 2010, he was head of Pfizer‘s Worldwide Policy group. He led a global team of professionals in: 1) worldwide government policy, 2) science policy, 3) economic policy and research, and 4) international policy. He advised the CEO on the company’s efforts in Healthcare Reform. Prior to joining Pfizer, Mr. Simon was the founding President of FasterCures/The Center for Accelerating Medical Solutions, an independent, nonpartisan organization that is a center of the California-based Milken Institute. There he led efforts to reform policies governing biopharmaceutical discovery and development, with the goal of bringing a greater number of lifesaving medicines more quickly to doctors and patients. Immediately prior to joining FasterCures, Mr. Simon was CEO of Simon Strategies and provided strategic advice to CEOs of major international firms such as Sony, Cisco, Netscape, Motorola, Sega and AOL.

Mr. Simon was Chief Domestic Policy Advisor to Vice President Al Gore from 1993 to 1997. He was the lead staffer for the Clinton-Gore Administration for development and passage of the Telecommunications Reform Act of 1996 as well as development of the National and Global Information Infrastructure. He represented the Vice President on the National Economic Council, helped negotiate the US-Russia agreement on the International Space Station and oversaw a number of key initiatives, including programs at the National Institutes of Health, the National Cancer Institute, the Food and Drug Administration, and the Human Genome Project. He was also instrumental in crafting the regulatory framework that is now the foundation for the biotechnology industry.

The journal Nature Medicine named Greg one of “Ten People to Watch” in health care policy, noting that he was among “a handful of influential people who quietly keep the wheels of biomedical science turning.” In 2010 he received the Genetic Alliance’s “Art of Advocacy” award. In May 2011 Greg was invited to be the second lecturer in the Constantin Spiegelfeld Lecture series of the Research Center for Molecular Medicine of the Austrian Academy of Sciences. He is a regular presenter at the Milken Institute Global Conference, the OECD, the Washington Campus (a nonprofit educational institution in Washington, D.C.) and at health conferences and academic institutions around the country.

Mr. Simon served as Sen. Gore`s Legislative Director from 1991 to 1993. He was Staff Director of the Investigations and Oversight Subcommittee of the U.S. House of Representatives Committee on Science, Space and Technology from 1985 to 1991. He received his law degree from the University of Washington in 1983 where he was a member of the Law Review and the Moot Court. He has a B.A. in history from the University of Arkansas. He is a resident of Bethesda, Maryland.

Roger Stein is the Managing Director of Research and Academic Relations globally at Moody’s Corporation. Prior to this, he was President of Moody’s Research Labs in New York. He has been actively engaged in developing new approaches to applied risk modeling for over 20 years. As the co-head of Moody’s KMV’s research and product development, Stein led the development of commercial risk management tools that have been adopted widely by hundreds of major financial institutions globally and he has worked extensively on developing techniques for model validation. Before MKMV, Stein led Moody’s Risk Management Services research group. He has authored over fifty professional and academic articles and books. Stein serves on the editorial boards of several finance-related journals and conducts research in a number of areas including credit risk, systemic risk and machine learning. He is the President and of the Consortium for Systemic Risk Analytics and serves on the board of Planet Finance, USA, on the Business Practices Council of the AACSB and on the Advisory Council of the Museum of Mathematics. He is a also Research Affiliate at the MIT Sloan School of Management. Stein has a PhD and Master’s degree from the Stern School of Business, New York University.

Vikas P. Sukhatme received a PhD in physics from MIT and an MD from Harvard Medical School. He is a physician engaged in both basic science and patient-oriented research at Harvard, where he is the Victor J. Aresty Professor of Medicine. He is also the Chief Academic Officer at Beth Israel Deaconess Medical Center, Boston. His primary interest is in cancer research but his research has spanned such diverse areas as toxemia of pregnancy and sepsis.

Kailash Swarna is a Senior Director at Millennium, The Takeda Oncology Company. He recently completed the MIT Sloan Fellows Program, Class of 2012. Mr. Swarna is the Founder and CEO of StarFire Biosciences ; a Los Angeles based early stage drug-discovery Company specializing in Oncology Therapeutics. He has held senior positions in R&D and business development at Abbott Labs, Amgen, GlaxoSmithKline, Jubilant Biosys, and Novartis. Mr. Swarna is also a member of the board of several early stage companies in the healthcare space and specializes in valuation, capital acquisition, and deal structuring.

J. Marty Tenenbaum, Cancer Commons. Please see steering committee members tab.

Tom Tombrello, Caltech. Please see steering committee members tab.

Frances Toneguzzo is Executive Director of Research Ventures & Licensing. Her team oversees the management and licensing of intellectual property and serves as the entry point for all industrial relationships relating to research, support of research or technology transfer. Prior to coming to Partners, Frances served as Director of the Office for Technology and Industry Collaboration at Tufts University/New England Medical Center and as Associate Director, responsible for intellectual property relating to the life sciences at Harvard University. She comes from the biotech industry, having played various technical and business development roles at big pharma (E. I Dupont & Co) as well as mid-sized (E.G.&G.Biomolecular) and startup companies (One Cell Systems). She holds a Ph.D. in Biochemistry from McMaster University in Canada.

Doug Treco has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc),a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. Previously, he was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School. He has authored numerous peer-reviewed publications and holds over 35 U.S. and European patents in the areas of protein production, gene mapping, and gene therapy. Doug is also an Entrepreneur-in-Residence with Morgenthaler Ventures. Doug received his Ph.D. in biochemistry and molecular biology from SUNY at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.

Thomas Unger is the Executive Director of Development Operations at Pfizer Inc. He recently transitioned into Pfizer’s Development Operations Group from his previous position in Worldwide Regulatory Strategy. A primary focus of his efforts at Pfizer has been to facilitate innovation in drug development by focusing on frameworks that improve the understanding, evaluation and communication of risk, based on the shared interests of companies, payors, providers, patients, and regulators to advance new medicines that improve public health. Prior to this role, Thomas was the head of Strategy and Operations for Pfizer’s Biotherapeutics and Bioinnovation Center. He joined Pfizer in 2005 as a member and head of the Strategic Management Group within Pfizer’s Global Research and Development (PGRD) organization, responsible for supporting the Worldwide Development Organization designing and executing scientific, clinical and operational programs.

Before joining Pfizer, Thomas held a number of senior strategic advisory positions including the investment banking and venture capital firms Aperion Partners, LLC and MTM Advisors, LLC, and the management consulting firms Wood Mackenzie Limited and PA Consulting Group. Thomas started his industry career as co-founder of a number of early stage biotechnology companies including BioLogic Technologies and Miragen Incorporated.

Thomas obtained his B.S. in Biology from the University of Southern California, his Ph.D. in Biological Sciences from the California College of Medicine, University of California, Irvine, and his M.B.A. from the Marshall School of Business, University of Southern California.

Chip Wallach is a Managing Director at Bank of America Merrill Lynch and assists a wide range of BofAML’s clients with their dealings with the rating agencies. He works with issuers as they face the rating agencies in a variety of contexts, including new debt issues, merger and acquisition activity, and shifts in corporate financial policy.

Mr. Wallach joined the BofAML’s Ratings Advisory Services Group in August 2001. From 1996 to 2001, he was a Managing Director in Bank of America’s Syndicated Debt Capital Markets Group providing coverage to a variety of sectors including retail, restaurants, utilities, and textile & apparel sectors. Prior to joining Bank of America, Mr. Wallach spent 6 years at The Chase Manhattan Bank. Mr. Wallach has an MBA in finance and marketing from Columbia Business School. He received his BA in economics from Haverford College.

Dr. Robert A. Weinberg is a founding member of the Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research at the Massachusetts Institute of Technology (MIT). He is also the first Director of the Ludwig Cancer Center at MIT. He is an internationally recognized authority on the genetic basis of human cancer. Dr. Weinberg and his colleagues isolated the first human cancer-causing gene, the ras oncogene, and the first known tumor suppressor gene, Rb, the retinoblastoma gene. The principal goal of his research program is to determine how oncogenes, their normal counterparts (proto-oncogenes), and tumor suppressor genes fit together in the complex circuitry that controls cell growth. More recently, his group has succeeded in creating the first genetically defined human cancer cells. He is particularly interested in applying this knowledge to improve the diagnosis and treatment of breast cancer. Dr. Weinberg is the author or editor of six books and more than 390 articles. He has written a comprehensive cancer textbook entitled “The Biology of Cancer”. His other books, intended for a lay audience, are “One Renegade Cell”, “Racing to the Beginning of the Road: The Search for the Origin of Cancer” and “Genes and the Biology of Cancer,” co-authored with Dr. Harold E. Varmus, former Director of the National Institutes of Health. He is an elected Member of the U.S. National Academy of Sciences and Fellow of the American Academy of Arts and Sciences. He is a Member of the American Philosophical Society and the Institute of Medicine.

Teri Willey is Vice President for Technology and Business Development at the Icahn School of Medicine at Mount Sinai. Ms. Willey joined Icahn School of Medicine at Mount Sinai (MSSM) in June 2011. Prior to MSSM she was Chief Executive of Cambridge Enterprise, Ltd the technology commercialization affiliate of the University of Cambridge; founder and Managing Partner of ARCH Development Partners (ADP), a seed and early stage venture fund focused on university and corporate spin-outs; University of Notre Dame Business School Adjunct Professor; and Vice President of Start-ups at ARCH Development Corporation, a subsidiary of the University of Chicago, which commercialised technology from the University and Argonne National Laboratory. Her prior experience also includes technology transfer and business development roles at Northwestern University, Purdue University and International Minerals and Chemical. Teri has been an advisor to policy makers, universities and companies and is a past President of the Association of University Technology Managers (AUTM).

Dr. Alastair Wood received his medical training at St Andrew’s University and Dundee Medical School in Scotland. Following fellowship training he joined the Faculty at Vanderbilt University School of Medicine where he remained to become tenured Professor of both Medicine and Pharmacology and Attending Physician at Vanderbilt Medical School. He was Assistant Vice Chancellor for Clinical Research (1999-2004), and Associate Dean, Vanderbilt Medical School (2004-2006) before being appointed Emeritus Professor of Medicine and Emeritus Professor of Pharmacology in 2006. His current academic appointments are Professor of Medicine and Professor of Pharmacology at Weill Cornell Medical College, New York. He is a Partner at Symphony Capital LLC, a New York based Private Equity Company managing over $300 million dedicated to investments in the clinical development of novel biopharmaceutical products.
Dr. Wood is a member of many societies and has received numerous honors, notably election to membership of The National Academy of Sciences’ Institute of Medicine, The American Association of Physicians (AAP), The American Society for Clinical Investigation (ASCI), Honorary Fellow, American Gynecological and Obstetrical Society (AGOS), Fellowship of The American College of Physicians, Fellowship of The Royal College of Physicians of London, and Fellowship of The Royal College of Physicians of Edinburgh. He was the 2005 recipient of the Rawls-Palmer Award in recognition of “Drug investigation that brings the effects of modern drug research to the care of patients” from the American Society for Pharmacology and Therapeutics and in 2008 received the honorary degree of Doctor of Laws, honoris causa, from the University of Dundee.

Dr. Wood has served on a number of Editorial Boards. He was a member of The New England Journal of Medicine Editorial Board (2004-2006); he was the Drug Therapy Editor of The New England Journal of Medicine from 1985 to 2004, and is currently on the Editorial Board of The British Journal of Clinical Pharmacology and The Scientist. He has previously served on the Editorial Boards of Clinical Pharmacology and Therapeutics and Biopharmaceutics and Drug Disposition. He authored the Chapter in Harrison’s Principles of Internal Medicine on Adverse Drug Reactions from the 9th through the 15th edition.

Dr. Wood was the chairman of the FDA’s Nonprescription Drugs Advisory Committee until 2006, and chaired the 2005 FDA Advisory Committee on Cox-2 inhibitors. He previously served as a member of the Cardiovascular and Renal Advisory Committee of the Food and Drug Administration, and the FDA’s Nonprescription Drugs Advisory Committee. Dr. Wood has also been both a member, and has chaired NIH Study Sections, and has served in a similar capacity for various philanthropic grant-giving bodies. He has served as a director of pharmaceutical companies including Antigenics (AGEN), Oxigene, Symphony Neurodevelopment, and Symphony Evolution.

He has also served as a consultant to pharmaceutical companies, investors and academic institutions. He has provided Congressional testimony, and directly interacted with and advised senior White House officials, legislators, and the Secretary of Health on matters related to public health. His research interests have been focused on understanding the mechanisms for interindividual variability in drug response. His research has resulted in over 300 articles, reviews and editorials.

Jake Xia is retiring in May 2013 from Morgan Stanley after 17 years where he served as a Managing Director, most recently as Head of Global Structured Rates trading, and a member of Morgan Stanley’s global Fixed Income Management Committee. Jake joined Morgan Stanley in New York in 1996, and worked in the offices of London, Hong Kong, Tokyo, Boston and New York. Jake became the Head of Interest Rates for Asia in 2006 and Co-Head of Fixed Income in Japan in 2008. Before moving back to the US in 2009, he was a member of Morgan Stanley’s Asia Executive Committee and Tokyo Management Committee. From 2009 to 2010, Jake served as the global head of Fixed Income Trading Risks, responsible for allocating risk capital and managing portfolio risks. Prior to Morgan Stanley, Jake worked in the Fixed Income Division of Salomon Brothers in New York and as a Research Scientist at Schlumberger-Doll Research in Connecticut. Jake holds a Ph.D. degree in Electrical Engineering and Computer Science from Massachusetts Institute of Technology (MIT), Cambridge, MA, and a B.S. degree from Beijing University, Beijing, China.

To make the conference as productive as possible, we created working groups comprised of individuals with domain-specific expertise for each of the sessions. These groups convened prior to the conference and were tasked with the goal of identifying the most significant challenges within their session topic and providing potential solutions to be presented at the conference and vetted by the broader set of conference participants.

• Credit Models and Debt Rating
• Financing Structure, Marketing, and Investor Concerns
• Government, Healthcare Reform, and Non-Profits
• New Business Models
• Scientific and Engineering Challenges
• Technology Licensing and Intellectual Property Issues

Material presented at CanceRx 2013 is available to conference participants only. Please CLICK HERE to access the password-protected area.